false Q1 0000820081 --12-31 Large Accelerated Filer false false true P3Y 0 P5Y 0 2025-05-31 2023-03-31 2029-11-30 0 P10Y4M24D P3Y 0000820081 2019-01-01 2019-03-31 xbrli:shares 0000820081 2019-04-29 iso4217:USD 0000820081 2019-03-31 0000820081 2018-12-31 iso4217:USD xbrli:shares 0000820081 us-gaap:ProductMember 2019-01-01 2019-03-31 0000820081 us-gaap:ProductMember 2018-01-01 2018-03-31 0000820081 us-gaap:ServiceMember 2019-01-01 2019-03-31 0000820081 us-gaap:ServiceMember 2018-01-01 2018-03-31 0000820081 2018-01-01 2018-03-31 0000820081 us-gaap:CommonStockMember 2018-12-31 0000820081 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000820081 us-gaap:RetainedEarningsMember 2018-12-31 0000820081 us-gaap:TreasuryStockMember 2018-12-31 0000820081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000820081 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000820081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000820081 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000820081 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000820081 us-gaap:CommonStockMember 2019-03-31 0000820081 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000820081 us-gaap:RetainedEarningsMember 2019-03-31 0000820081 us-gaap:TreasuryStockMember 2019-03-31 0000820081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000820081 us-gaap:CommonStockMember 2017-12-31 0000820081 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000820081 us-gaap:RetainedEarningsMember 2017-12-31 0000820081 us-gaap:TreasuryStockMember 2017-12-31 0000820081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000820081 2017-12-31 0000820081 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000820081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000820081 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000820081 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000820081 us-gaap:CommonStockMember 2018-03-31 0000820081 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000820081 us-gaap:RetainedEarningsMember 2018-03-31 0000820081 us-gaap:TreasuryStockMember 2018-03-31 0000820081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000820081 2018-03-31 cbm:Segment 0000820081 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000820081 cbm:SingleUseProductsMember 2019-01-01 2019-03-31 0000820081 cbm:SingleUseProductsMember 2018-01-01 2018-03-31 0000820081 cbm:MultiUseProductsMember 2019-01-01 2019-03-31 0000820081 cbm:MultiUseProductsMember 2018-01-01 2018-03-31 0000820081 cbm:ServiceRevenueMember 2019-01-01 2019-03-31 0000820081 cbm:ServiceRevenueMember 2018-01-01 2018-03-31 xbrli:pure 0000820081 cbm:AvistaPharmaSolutionsMember 2019-01-02 0000820081 cbm:AvistaPharmaSolutionsMember 2019-01-01 2019-01-02 0000820081 cbm:AvistaPharmaSolutionsMember us-gaap:CustomerRelationshipsMember 2019-01-02 0000820081 cbm:TransactionCostsMember cbm:AvistaPharmaSolutionsMember 2019-01-01 2019-03-31 0000820081 cbm:OtherAcquisitionAndIntegrationRelatedExpensesMember 2019-01-01 2019-03-31 0000820081 cbm:AvistaPharmaSolutionsMember 2019-01-01 2019-03-31 0000820081 cbm:HaloPharmaMember 2018-09-12 0000820081 cbm:HaloPharmaMember 2019-03-31 0000820081 cbm:DrugProductMember 2019-03-31 0000820081 cbm:EarlyStageDevelopmentAndTestingMember 2019-03-31 0000820081 cbm:InternalUseSoftwareMember srt:MinimumMember 2019-01-01 2019-03-31 0000820081 cbm:InternalUseSoftwareMember srt:MaximumMember 2019-01-01 2019-03-31 0000820081 us-gaap:CustomerRelatedIntangibleAssetsMember srt:MinimumMember 2019-01-01 2019-03-31 0000820081 us-gaap:CustomerRelatedIntangibleAssetsMember srt:MaximumMember 2019-01-01 2019-03-31 0000820081 cbm:InternalUseSoftwareMember 2019-03-31 0000820081 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-03-31 0000820081 us-gaap:CustomerRelatedIntangibleAssetsMember 2019-03-31 0000820081 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-03-31 0000820081 srt:MinimumMember cbm:InternalUseSoftwareMember 2018-01-01 2018-12-31 0000820081 cbm:InternalUseSoftwareMember srt:MaximumMember 2018-01-01 2018-12-31 0000820081 srt:MinimumMember us-gaap:CustomerRelatedIntangibleAssetsMember 2018-01-01 2018-12-31 0000820081 us-gaap:CustomerRelatedIntangibleAssetsMember srt:MaximumMember 2018-01-01 2018-12-31 0000820081 cbm:InternalUseSoftwareMember 2018-12-31 0000820081 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0000820081 us-gaap:CustomerRelatedIntangibleAssetsMember 2018-12-31 0000820081 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-01-01 2018-12-31 0000820081 us-gaap:ComputerSoftwareIntangibleAssetMember cbm:AvistaPharmaSolutionsMember 2019-01-02 0000820081 cbm:HaloPharmaMember 2019-01-01 2019-03-31 0000820081 cbm:SyndicatedSeniorCreditFacilityMember 2019-01-02 0000820081 us-gaap:RevolvingCreditFacilityMember 2019-01-02 0000820081 cbm:SyndicatedSeniorCreditFacilityMember cbm:TermLoanAMember 2019-01-02 0000820081 cbm:SyndicatedSeniorCreditFacilityMember 2019-01-01 2019-01-02 0000820081 cbm:SyndicatedSeniorCreditFacilityMember cbm:TermLoanAThroughDecemberTwoThousandTwentyMember 2019-01-01 2019-01-02 0000820081 cbm:SyndicatedSeniorCreditFacilityMember cbm:TermLoanAThroughDecemberTwoThousandTwentyTwoMember 2019-01-01 2019-01-02 0000820081 cbm:SyndicatedSeniorCreditFacilityMember cbm:TermLoanAThroughDecemberTwoThousandTwentyThreeMember 2019-01-01 2019-01-02 0000820081 srt:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember cbm:SyndicatedSeniorCreditFacilityMember 2019-01-01 2019-01-02 0000820081 srt:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember cbm:SyndicatedSeniorCreditFacilityMember 2019-01-01 2019-01-02 0000820081 cbm:SyndicatedSeniorCreditFacilityMember 2019-03-31 0000820081 cbm:SyndicatedSeniorCreditFacilityMember 2018-03-31 0000820081 cbm:SyndicatedSeniorCreditFacilityMember 2019-01-01 2019-03-31 0000820081 us-gaap:ForeignExchangeContractMember 2019-03-31 0000820081 us-gaap:ForeignExchangeContractMember 2018-12-31 0000820081 us-gaap:SwapMember 2019-03-31 0000820081 us-gaap:SwapMember 2018-12-31 0000820081 us-gaap:SwapMember 2019-01-01 2019-03-31 0000820081 us-gaap:SwapMember cbm:LIBORRisesByHundredBasisPointsMember 2019-01-01 2019-03-31 0000820081 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-03-31 0000820081 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000820081 2018-06-30 0000820081 cbm:ManufacturingOfficeAndWarehouseSpaceMember 2019-01-01 2019-03-31 0000820081 srt:MinimumMember cbm:ManufacturingOfficeAndWarehouseSpaceMember 2019-03-31 0000820081 srt:MaximumMember cbm:ManufacturingOfficeAndWarehouseSpaceMember 2019-03-31 0000820081 cbm:ManufacturingAndOfficeFacilitiesMember stpr:CO 2019-01-01 2019-03-31 0000820081 cbm:ManufacturingAndOfficeFacilitiesMember stpr:NC 2019-01-01 2019-03-31 0000820081 cbm:OfficeSpaceMember stpr:NJ 2019-01-01 2019-03-31 0000820081 cbm:NonCancelableOperatingLeaseMember 2018-12-31 0000820081 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000820081 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000820081 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000820081 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000820081 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000820081 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000820081 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-03-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-03-31 0000820081 us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-03-31 0000820081 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000820081 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000820081 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000820081 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000820081 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000820081 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000820081 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0000820081 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000820081 us-gaap:EmployeeStockOptionMember 2019-03-31 0000820081 us-gaap:EmployeeStockOptionMember 2018-12-31 0000820081 us-gaap:RestrictedStockMember 2018-12-31 0000820081 us-gaap:PerformanceSharesMember 2018-12-31 0000820081 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0000820081 us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0000820081 us-gaap:RestrictedStockMember 2019-03-31 0000820081 us-gaap:PerformanceSharesMember 2019-03-31 0000820081 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0000820081 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000820081 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0000820081 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000820081 us-gaap:PensionPlansDefinedBenefitMember country:US 2019-01-01 2019-03-31 0000820081 us-gaap:PensionPlansDefinedBenefitMember country:US 2018-01-01 2018-03-31 0000820081 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2019-01-01 2019-03-31 0000820081 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2018-01-01 2018-03-31 0000820081 cbm:DrugSubstanceMember 2019-01-01 2019-03-31 0000820081 cbm:DrugSubstanceMember 2018-01-01 2018-03-31 0000820081 cbm:DrugProductMember 2019-01-01 2019-03-31 0000820081 cbm:EarlyStageDevelopmentAndTestingMember 2019-01-01 2019-03-31 0000820081 cbm:EarlyStageDevelopmentAndTestingMember 2018-01-01 2018-03-31 0000820081 cbm:AllSegmentsMember 2019-01-01 2019-03-31 0000820081 cbm:AllSegmentsMember 2018-01-01 2018-03-31 0000820081 us-gaap:CorporateMember 2019-01-01 2019-03-31 0000820081 us-gaap:CorporateMember 2018-01-01 2018-03-31 0000820081 us-gaap:OtherNoncurrentLiabilitiesMember 2019-03-31 0000820081 us-gaap:OtherNoncurrentLiabilitiesMember 2018-12-31 0000820081 cbm:BayonneMember 2019-03-31 0000820081 cbm:CliftonAndCarlstadtMember 2019-03-31 cbm:Subsidiary 0000820081 cbm:BerrysCreekSiteMember 2019-01-01 2019-03-31 0000820081 cbm:BerrysCreekSiteMember 2019-03-31 0000820081 cbm:MaybrookSiteMember 2019-03-31 0000820081 srt:MinimumMember cbm:HarrimanSiteMember 2019-01-01 2019-03-31 0000820081 srt:MaximumMember cbm:HarrimanSiteMember 2019-01-01 2019-03-31 0000820081 cbm:HarrimanSiteMember 2019-03-31 0000820081 cbm:ScientificChemicalProcessingScpSuperfundSiteMember 2019-03-31 cbm:Site 0000820081 cbm:ScientificChemicalProcessingScpSuperfundSiteMember 2019-01-01 2019-03-31 0000820081 cbm:NewarkBayComplexLitigationMember 2019-03-31 utr:sqmi 0000820081 cbm:NewarkBayComplexLitigationMember 2019-01-01 2019-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the quarterly period ended ~~September~~March 3031, ~~2018~~2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from to

Commission file number 1-10638

CAMBREX CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE		22-2476135
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

ONE MEADOWLANDS PLAZA, EAST RUTHERFORD, NEW JERSEY 07073

(Address of principal executive offices)

(201) 804-3000

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~October~~April 3129, ~~2018~~2019, ~~there~~the ~~were~~registrant had 33,~~560~~656,~~061~~015 shares ~~outstanding~~ of ~~the~~common ~~registrant’s Common Stock~~stock, $.10 par value per share, outstanding.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $.10 par value

CBM

New York Stock Exchange

CAMBREX CORPORATION AND SUBSIDIARIES

Table of Contents

				Page No.	~~Page No.~~
Part I	Financial Information	~~Financial Information~~
	Item 1.	~~Item~~Financial 1.Statements		~~Financial Statements~~
		Consolidated Balance Sheets	~~Consolidated Balance Sheets~~	3	3
		Consolidated Income Statements	~~Consolidated Income Statements~~	4	4
		Consolidated Statements of Comprehensive Income	~~Consolidated Statements of Comprehensive Income~~	5	5
			Consolidated Statements of Cash Flows		6
		Consolidated Statements of Stockholders’ Equity		6
			Notes to Consolidated Financial Statements		7
		Consolidated Statements of Cash Flows		7
	Item 2.		Management's Discussion and Analysis of Financial Condition and Results of Operations		32
		Notes to Consolidated Financial Statements		8
	Item 3.		Quantitative and Qualitative Disclosures about Market Risk		44
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations		30
	Item 4.		Controls and Procedures		44
	Item 3.	Quantitative and Qualitative Disclosures about Market Risk		35
Part II	Other Information
	Item 4.	Controls and Procedures		35
	Item 1.		Legal Proceedings		45
Part II	Other Information
	Item 1A.		Risk Factors		45
	Item 1.	Legal Proceedings		36
	Item 6.		Exhibits		45
	Item 1A.	Risk Factors		36
Signatures					46
	Item 6.	Exhibits		36
Signatures				37

Forward-Looking Statements

This document contains “forward-looking statements,” including statements or tables regarding expected performance. These and other forward-looking statements may be identified by the fact that they use words such as “guidance,” “expects,” “anticipates,” “intends,” “estimates,” “believes” or similar expressions. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. The factors described in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the period ended December 31, ~~2017~~2018 captioned “Risk Factors,” or otherwise described in the Company’s filings with the ~~SEC~~Securities and Exchange Commission, provide examples of such risks and uncertainties that may cause the Company’s actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, the possibility that the benefits from ~~the~~acquisitions ~~acquisition~~(including of Halo Pharma and Avista Pharma Solutions) may not be as anticipated, customer and product concentration, the Company’s ability to ~~win~~secure new customer contracts and renew existing contracts on favorable terms, significant declines in sales of products to the Company’s customers, pharmaceutical outsourcing trends, competitive pricing, or product developments, market acceptance and adoption rate of ~~its~~ customers’ products, government legislation and regulations (~~including~~particularly ~~those pertaining to~~ environmental issues), tax ~~rate~~rates, interest ~~rate~~rates, technology, manufacturing and legal issues, including the outcome of outstanding litigation, environmental matters, changes in foreign exchange rates, uncollectible receivables, the timing and/or volume of orders or shipments and the Company’s ability to meet its production plan and customer delivery schedules, expected timing of completion of capacity expansions, our ability to successfully integrate acquired businesses, ~~loss on disposition of assets,~~ cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company’s ability to receive regulatory approvals for its products, continued demand in the U.S. for late stage clinical products and the successful outcome of the Company’s investment in new products.

For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, ~~2017~~2018, including the Forward-Looking Statement sections therein, and other filings with the SEC. The Company cautions investors and potential investors not to place undue reliance on the forward-looking statements contained in this Quarterly Report on Form 10-Q and to give careful consideration to the risks and uncertainties listed above and contained in the Company’s SEC filings. The forward-looking statements in this Quarterly Report on Form 10-Q speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

Part I - FINANCIAL INFORMATION

Item 1.

Financial Statements

CAMBREX CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

(in thousands, except share data)

	September 30,			December 31,
	March 31,			December 31,
	2018			2017
	2019			2018
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	9767,~~135~~539		$	~~183~~95,~~284~~852
Trade receivables, net		7179,~~582~~098			75146,~~144~~330
Contract assets		~~112~~76,~~845~~069			-33,490
Other receivables		1410,~~824~~957			205,~~891~~198
Inventories, net		~~103~~119,~~648~~530			~~138~~111,~~542~~062
Prepaid expenses and other current assets		1619,~~776~~832			418,~~217~~160
Total current assets		~~416~~373,~~810~~025			~~422~~410,~~078~~092
Property, plant and equipment, net		~~352~~398,~~947~~774			~~254~~360,~~299~~528
Goodwill		271,424			43,626
Right of use assets		37,260			-
Intangible assets, net		191,959			13,868
Goodwill		407,512			261,095
Deferred income taxes		11,557			3,198
Intangible assets, net		256,504			187,205
Other non-current assets		35,~~192~~736			3,~~496~~099
Total assets	$	1,247,889		$	740,565
Deferred income taxes		9,979			1,409
Total assets	$	1,488,790		$	1,223,428
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	3850,~~205~~717		$	3547,~~017~~012
Contract liabilities, current		1015,~~269~~227			411,~~707~~713
Taxes payable		24,~~727~~450			431,651
Accrued expenses and other current liabilities		40,578			42,774
Operating lease liabilities, current		2,709			-
Total current liabilities		91,779			82,541
Current portion of long-term debt		10,000			-
Long-term debt		325,000			-
Accrued expenses and other current liabilities		42,750			44,036
Contract liabilities, non-current		43,379			39,000
Total current liabilities		125,853			104,412
Deferred income taxes		66,231			7,806
Contract liabilities, non-current		43,052			42,701
Accrued pension benefits		38,429			41,141
Long-term debt		487,500			300,000
Other non-current liabilities		23,793			25,213
Deferred income taxes		72,971			57,276
Total liabilities		588,611			195,701
Operating lease liabilities, non-current		34,658			-
Accrued pension benefits		41,373			42,218
Other non-current liabilities		24,056			23,094
Total liabilities		829,463			569,701
Stockholders' equity:
Common stock, $.10 par value; authorized 100,000,000, issued 34,813,949 and 34,270,975 shares at respective dates		3,481			3,427
Common stock, $.10 par value; authorized 100,000,000, issued 34,920,124 and 34,870,124 shares at respective dates		3,492			3,487
Additional paid-in capital		~~181~~184,~~435~~410			~~165~~182,~~979~~691
Retained earnings		~~537~~548,~~251~~872			~~429~~538,~~826~~463
Treasury stock, at cost, 1,273,888 and 1,424,153 shares at respective dates		(10,860	)		(12,140	)
Treasury stock, at cost, 1,264,109 and 1,264,109 shares at respective dates		(10,777	)		(10,777	)
Accumulated other comprehensive loss		(5266,~~029~~670	)		(4260,~~228~~137	)
Total stockholders' equity		659,~~278~~327			~~544~~653,~~864~~727
Total liabilities and stockholders' equity	$	1,~~247~~488,~~889~~790		$	~~740~~1,~~565~~223,428

See accompanying notes to unaudited consolidated financial statements.

CAMBREX CORPORATION AND SUBSIDIARIES

Consolidated Income Statements

(unaudited – in thousands, except per share data)

	Three Months Ended						~~Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2018			2017			2018			2017
	2019			2018
Gross sales	$	104,231		$	112,233		$	390,575		$	350,431
Product sales	$	124,245		$	135,459
Commissions, allowances and rebates		240			225			641			1,468
Service revenue		33,975			3,671
Net sales		103,991			112,008			389,934			348,963
Gross sales		158,220			139,130
Other revenues, net		627			611			7,827			3,216
Commissions, allowances and rebates		287			209
Net revenue		104,618			112,619			397,761			352,179
Net sales		157,933			138,921
Cost of goods sold		71,893			65,676			249,389			200,802
Other revenues, net		1,523			2,176
Gross profit		32,725			46,943			148,372			151,377
Net revenue		159,456			141,097
Operating expenses:
Cost of goods sold - product sales		78,805			86,583
Selling, general and administrative expenses		14,514			17,167			47,037			50,678
Cost of goods sold - service revenue		25,768			3,659
Research and development expenses		4,191			4,233			11,943			12,590
Total cost of goods sold		104,573			90,242
Acquisition and integration expenses		7,388			-			7,727			-
Gross profit		54,883			50,855
Total operating expenses		26,093			21,400			66,707			63,268
Operating expenses:
Operating profit		6,632			25,543			81,665			88,109
Selling, general and administrative expenses		25,041			16,855
Other expenses/(income):
Research and development expenses		3,462			3,619
Interest expense, net		725			337			824			991
Acquisition and integration expenses		6,056			-
Unrealized gain on investment in equity securities		(5,611	)		-			(10,757	)		-
Total operating expenses		34,559			20,474
Other expenses, net		109			432			554			1,119
Operating profit		20,324			30,381
Income before income taxes		11,409			24,774			91,044			85,999
Other expenses/(income):
(Benefit)/provision for income taxes		(15,406	)		7,498			(872	)		22,484
Interest expense, net		5,624			82
Income from continuing operations		26,815			17,276			91,916			63,515
Unrealized loss on investment in equity securities		569			-
(Loss)/income from discontinued operations, net of tax		(86	)		20			(710	)		(1,324	)
Other expenses, net		72			264
Net income	$	26,729		$	17,296		$	91,206		$	62,191
Income before income taxes		14,059			30,035
Basic earnings/(loss) per share of common stock:
Provision for income taxes		3,532			5,786
Income from continuing operations	$	~~0.80~~10,527		$	~~0.53~~24,249		$	~~2.77~~		$	~~1.95~~
Loss from discontinued operations, net of tax	$	(~~0.00~~118	)	$	~~0.00~~(191	)	$	~~(0.02~~	)	$	~~(0.04~~	)
Net income	$	~~0.80~~10,409		$	~~0.53~~24,058		$	~~2.75~~		$	~~1.91~~
Diluted earnings/(loss) per share of common stock:
Basic earnings/(loss) per share of common stock:
Income from continuing operations	$	0.7931		$	0.5274		$	~~2.73~~		$	~~1.90~~
Loss from discontinued operations, net of tax	$	(0.00	)	$	(0.0001	)	$	~~(0.02~~	)	$	~~(0.04~~	)
Net income	$	0.7931		$	0.5273		$	~~2.71~~		$	~~1.86~~
Weighted average shares outstanding:
Diluted earnings/(loss) per share of common stock:
Basic		33,406			32,749			33,130			32,612
Income from continuing operations	$	0.31		$	0.72
Effect of dilutive stock based compensation		486			763			573			839
Loss from discontinued operations, net of tax	$	(0.00	)	$	(0.00	)
Diluted		33,892			33,512			33,703			33,451
Net income	$	0.31		$	0.72
Weighted average shares outstanding:
Basic		33,632			32,894
Effect of dilutive stock based compensation		119			727
Diluted		33,751			33,621

See accompanying notes to unaudited consolidated financial statements.

CAMBREX CORPORATION AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income

(unaudited – in thousands)

	Three Months Ended					~~Nine Months Ended~~
	September 30,					September 30,
	March 31,
	2018			2017		2018			2017
	2019			2018
Net income	$	2610,~~729~~409		$	1724,~~296~~058	$	~~91,206~~		$	~~62,191~~
Other comprehensive income/(loss):
Foreign currency translation adjustments		32(4,778	)		72,~~006~~929		~~(10,504~~	)		~~19,753~~
Pension plan amortization of net actuarial loss and prior service cost, net of tax of $69, $118, $246 and $350 at respective dates		202			250		703			737
Interest rate swap, net of tax of $779 and $0 at respective dates		(1,996	)		-
Comprehensive income	$	26,963		$	24,552	$	81,405		$	82,681
Pension plan amortization of net actuarial loss and prior service cost, net of tax of $82 and $108 at respective dates		241			295
Comprehensive income	$	3,876		$	27,282

See accompanying notes to unaudited consolidated financial statements.

CAMBREX CORPORATION AND SUBSIDIARIES

Consolidated Statements of Stockholders’ Equity

(unaudited – in thousands, except share data)

	Common Stock
	Shares Issued		Par Value ($.10)		Additional Paid-In Capital			Retained Earnings		Treasury Stock			Accumulated Other Comprehensive Loss			Total Stockholders' Equity
Balance at December 31, 2018		34,870,124	$	3,487	$	182,691		$	538,463	$	(10,777	)	$	(60,137	)	$	653,727
Net income									10,409								10,409
Other comprehensive loss														(6,533	)		(6,533	)
Exercise of stock options		4,000				65											65
Issuance of performance shares		46,000		5		(5	)										-
Stock option expense						1,062											1,062
Restricted stock expense						96											96
Performance share expense						501											501
Balance at March 31, 2019		34,920,124	$	3,492	$	184,410		$	548,872	$	(10,777	)	$	(66,670	)	$	659,327



	Common Stock
	Shares Issued		Par Value ($.10)		Additional Paid-In Capital			Retained Earnings		Treasury Stock			Accumulated Other Comprehensive Loss			Total Stockholders' Equity
Balance at December 31, 2017		34,270,975	$	3,427	$	165,979		$	429,826	$	(12,140	)	$	(42,228	)	$	544,864
Balance at January 1, 2018, as previously reported		34,270,975		3,427		165,979			429,826		(12,140	)		(42,228	)		544,864
Impact of change in accounting policy									16,219								16,219
Adjusted balance at January 1, 2018		34,270,975	$	3,427	$	165,979		$	446,045	$	(12,140	)	$	(42,228	)	$	561,083
Net income									24,058								24,058
Other comprehensive income														3,224			3,224
Exercise of stock options		112,669		11		2,711											2,722
Stock option expense						1,039											1,039
Restricted stock expense						6											6
Performance share expense						605											605
Balance at March 31, 2018		34,383,644	$	3,438	$	170,340		$	470,103	$	(12,140	)	$	(39,004	)	$	592,737

See accompanying notes to unaudited consolidated financial statements.

CAMBREX CORPORATION AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(unaudited – in thousands)

	Nine Months Ended
	Three Months Ended
	September 30,
	March 31,
	2018			2017
	2019			2018
Cash flows from operating activities:
Net income	$	9110,~~206~~409		$	6224,~~191~~058
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		2414,~~203~~702			237,~~023~~517
Non-cash deferred revenue		(12,~~116~~543	)		(~~4,991~~808	)
Increase in inventory reserve		52,~~687~~314			32,~~217~~481
Unrealized gain on investment in equity securities		(10,757	)		-
Unrealized loss on investment in equity securities		569			-
Unrealized gain on foreign currency contracts		(~~1,582~~562	)		-
Stock based compensation		41,~~106~~659			61,~~321~~650
Deferred income tax provision		~~(14,025~~558	)		~~1,087~~682
Other		~~(146~~1,022	)		~~516~~(353	)
Changes in assets and liabilities:
Account receivables		12,144			35,995
Trade receivables		75,527			22,157
Contract assets		(5838,~~147~~629	)		-(37,280	)
Inventories		1(12,~~747~~596	)		(~~38,245~~58	)
Prepaid expenses and other current assets		(6,~~446~~390	)		(701,241	)
Accounts payable and other current liabilities		(171,~~476~~297	)		~~(16~~4,~~422~~124	)
Contract liabilities, current		~~471~~924			~~512~~1,161
Other non-current assets and liabilities		(~~3,338~~44	)		~~(2,282~~388	)
Discontinued operations:
Non-current liabilities		~~898~~152			~~2,418~~265
Net cash used in discontinued operations		(~~557~~217	)		(~~1,185~~292	)
Net cash provided by operating activities		3945,~~764~~558			7224,~~085~~451
Cash flows from investing activities:
Capital expenditures		(4319,~~545~~237	)		(3823,~~241~~791	)
Proceeds from sale of business		-			2,836
Acquisition of businesses, net of cash acquired		(248,467	)		-
Acquisition of business, net of cash acquired		(418,963	)		-
Net cash used in investing activities		(267,704	)		(23,791	)
Net cash used in investing activities		(462,508	)		(35,405	)
Cash flows from financing activities:
Borrowings		~~325~~220,000			-
Proceeds from stock options exercised		12,685			3,448
Repayments		(22,500	)		-
Net cash provided by financing activities		337,685			3,448
Debt issuance costs		(2,836	)		-
Effect of exchange rate changes on cash and cash equivalents		(1,090	)		4,134
Principal payments under finance lease obligations		(276	)		-
Net (decrease)/increase in cash and cash equivalents		(86,149	)		44,262
Proceeds from stock options exercised		65			2,722
Cash and cash equivalents at beginning of period		183,284			74,141
Net cash provided by financing activities		194,453			2,722
Cash and cash equivalents at end of period	$	97,135		$	118,403
Effect of exchange rate changes on cash and cash equivalents		(620	)		902
Net (decrease)/increase in cash and cash equivalents		(28,313	)		4,284
Cash and cash equivalents at beginning of period		95,852			183,284
Cash and cash equivalents at end of period	$	67,539		$	187,568

See accompanying notes to unaudited consolidated financial statements.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

(1)	Basis of Presentation

Unless otherwise indicated by the context, "Cambrex" or the "Company" means Cambrex Corporation and subsidiaries.

On September 12, 2018, the Company acquired Halo Pharma (“Halo”) and on January 2, 2019 the Company acquired Avista Pharma Solutions (“Avista”). The results of Halo and Avista have been included in the consolidated results since ~~the~~their respective acquisition ~~date~~dates. AsDue ato ~~result~~the ofacquisitions and to be consistent with how the ~~acquisition~~business ofis ~~Halo~~managed, the Company now reports its results in ~~two~~three segments, ~~Active~~Drug ~~Pharmaceutical~~Substance ~~Ingredients~~(“DS”), Drug Product (“~~API’s~~DP”) and ~~Finished~~Early ~~Dosage~~Stage ~~Form~~Development and Testing (“~~FDF~~ESDT”). See Note 4 for additional information on the ~~Halo~~acquisitions ~~acquisition~~and Note 15 for additional segment information.

The accompanying unaudited consolidated financial statements have been prepared from the records of the Company. In the opinion of management, the financial statements include all adjustments, which are of a normal and recurring nature, except as otherwise described herein, and are necessary for a fair statement of financial position and results of operations in conformity with U.S. generally accepted accounting principles (“GAAP”). These interim financial statements should be read in conjunction with the financial statements for the year ended December 31, ~~2017~~2018.

The results of operations of any interim period are not necessarily indicative of the results expected for the full year.

For all periods presented, financial results for discontinued operations relate to environmental investigation and remediation at sites of divested businesses.

Certain reclassifications have been made to prior year amounts to conform with the current year presentation.

(2)	Impact of Recently Issued Accounting Pronouncements

The following accounting pronouncements became effective for the Company January 1, ~~2018~~2019:

~~Revenue from Contracts with Customers~~Leases

In ~~May~~February ~~2014~~2016, the FASB issued ASU ~~2014~~2016-0902 which ~~introduces~~requires alessees ~~new~~to ~~five-step~~recognize ~~revenue~~right ~~recognition~~of ~~model~~use inassets ~~which~~and anlease ~~entity~~liabilities ~~should~~on ~~recognize~~the ~~revenue~~balance tosheet ~~depict~~for ~~the~~all ~~transfer~~leases ofwith ~~promised~~terms ~~goods~~greater orthan ~~services~~twelve tomonths. Several ~~customers~~updates were issued in an2018 ~~amount~~and 2019 that ~~reflects~~provide ~~the~~clarification ~~consideration~~on toa ~~which~~number of specific issues and reporting requirements. This standard became effective for the ~~entity~~Company ~~expects~~on toJanuary be1, ~~entitled~~2019. As ina ~~exchange~~result of adopting this update, right of use assets of $37,984 and operating lease liabilities of a similar amount were recorded on the balance sheet for ~~those~~identified ~~goods~~operating orleases. ~~services~~See Note 11.

OnImprovements ~~January 1, 2018, the Company adopted the new accounting standard ASC Topic 606, Revenue from Contracts with Customers and all the related amendments (“new revenue standard”)~~ to ~~all~~Nonemployee ~~contracts~~Share-Based ~~not~~Payment completed as of January 1, 2018 using the modified retrospective method. The cumulative effect of initially applying the new revenue standard was $16,219 and has been recorded as an adjustment to increase the opening balance of retained earnings. The cumulative effect adjustment relates primarily to the recognition of revenue and costs for contracts that transfer promised goods or services over time. Gross sales, cost of goods sold, and tax expense of $51,896, $31,347, and $4,330 respectively, were recorded as part of the cumulative effect adjustment. The comparative information has not been restated and is reported in accordance with accounting standard Topic 605, which was in effect for those periods.Accounting

7In June 2018, the FASB issued ASU 2018-07 which aligns the accounting for share-based payment awards issued to nonemployees with those issued to employees. Under the new guidance, the nonemployee awards will be measured on the grant date and compensation costs will be recognized when achievement of the performance condition is probable. The update became effective on January 1, 2019 and did not have a material impact on the Company’s consolidated financial statements.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

The adoption of the new revenue standard impacted the consolidated financial statements as follows:

Income Statement

	For the Three Months Ended September 30, 2018
	As Reported			Effect of Change			Amount Without Adoption of ASC 606
Gross sales	$	104,231		$	1,914		$	102,317
Net revenue		104,618			1,914			102,704
Cost of goods sold		71,893			8,475			63,418
Gross profit		32,725			(6,561	)		39,286
Operating profit		6,632			(6,561	)		13,193
Benefit for income taxes		(15,406	)		(1,558	)		(13,848	)
Income from continuing operations		26,815			(5,003	)		31,818
Net income		26,729			(5,003	)		31,732
Diluted earnings per share from continuing operations		0.79			(0.15	)		0.94

	For the Nine Months Ended September 30, 2018
	As Reported			Effect of Change		Amount Without Adoption of ASC 606
Gross sales	$	390,575		$	58,182	$	332,393
Net revenue		397,761			58,182		339,579
Cost of goods sold		249,389			33,194		216,195
Gross profit		148,372			24,988		123,384
Operating profit		81,665			24,988		56,677
(Benefit)/provision for income taxes		(872	)		5,076		(5,948	)
Income from continuing operations		91,916			19,912		72,004
Net income		91,206			19,912		71,294
Diluted earnings per share from continuing operations		2.73			0.59		2.14

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

~~Balance~~Targeted ~~Sheet~~Improvements to Accounting for Hedging Activities

	September 30, 2018
	As Reported		Effect of Change			Balances Without Adoption of ASC 606
Current Assets
Contract assets	$	112,845	$	112,845		$	-
Inventory		103,648		(66,905	)		170,553
Current Liabilities
Taxes payable		2,727		9,405			(6,678	)
Stockholders' Equity
Retained earnings		537,251		36,131			501,120

In August 2017, the FASB issued ASU 2017-12 which improves the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. The standard also makes certain targeted improvements to simplify the application of the hedge accounting guidance. The update became effective on January 1, 2019 and did not have a material impact on the Company’s consolidated financial statements.

Presentation of Net Periodic Benefit Cost Related to Defined Benefit Plans

In March 2017, the FASB issued ASU 2017-07 which amends the requirements in ASC 715 related to the income statement presentation of the components of net periodic benefit cost for an entity’s sponsored defined pension and other postretirement plans. The ASU requires entities to disaggregate the current-service-cost component from the other components of net benefit cost and present it with other current compensation costs for related employees in the income statement and present the other components elsewhere in the income statement and outside of income from operations if such subtotal is presented. This standard became effective for the Company on January 1, 2018. For the three and nine months ended September 30, 2018, the Company recorded $167 and $649, respectively, to “Other expenses, net” which formerly would have been recorded as “Selling, general and administrative expenses” or “Cost of goods sold.” To conform to the current year presentation, for the three and nine months ended September 30, 2017 the Company reclassified $384 and $1,107, respectively, from “Selling, general and administrative expenses” and $54 and $161, respectively, from “Cost of goods sold” to “Other expenses, net.”

Scope of Modification Accounting, Stock Based Compensation

In May 2017, the FASB issued ASU 2017-09 which provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered non-substantive. The update became effective on January 1, 2018 and did not have a material impact on the Company’s consolidated financial statements.

Business Combinations – Clarifying the Definition of a Business

In January 2017, the FASB issued ASU 2017-01 which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen for determining when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and a substantive process that contribute to an output to be considered a business. The amendment became effective on January 1, 2018 and did not have a material impact on the Company’s consolidated financial statements.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments

In August 2016, the FASB issued ASU 2016-15 which provides guidance on the presentation and classification in the statement of cash flows for specific cash receipt and payment transactions, including debt prepayment or extinguishment costs, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims and corporate-owned life insurance policies, and distributions received from equity method investees. The standard became effective on January 1, 2018 and did not have a material impact on the Company’s consolidated financial statements.

Statement of Cash Flows – Restricted Cash

In November 2016, the FASB issued ASU 2016-18 which clarifies the presentation requirements of restricted cash within the statement of cash flows. The changes in restricted cash and restricted cash equivalents during the period should be included in the beginning and ending cash and cash equivalents balance reconciliation on the statement of cash flows. When cash, cash equivalents, restricted cash or restricted cash equivalents are presented in more than one line item within the statement of financial position, an entity shall calculate a total cash amount in a narrative or tabular format that agrees to the amount shown on the statement of cash flows. Details on the nature and amounts of restricted cash should also be disclosed. The update became effective on January 1, 2018 and did not have a material impact on the Company’s consolidated financial statements.

Recognition and Measurement of Financial Assets and Financial Liabilities

In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU amends guidance on the classification and measurement of financial instruments, including significant revisions in accounting related to the classification and measurement of investments in equity securities and presentation of certain fair value changes for financial liabilities when the fair value option is elected. The ASU requires equity securities to be measured at fair value with changes in fair value recognized through net earnings and amends certain disclosure requirements associated with the fair value of financial instruments. In the period of adoption, the Company is required to reclassify the unrealized gains/losses on equity securities within accumulated other comprehensive income/(loss) to retained earnings. In February 2018, the FASB issued ASU 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10), which clarified certain aspects of the previously issued ASU. The ASU was adopted by the Company on January 1, 2018 and did not have a material effect on the Company’s consolidated financial statements.

The following recently issued accounting pronouncements will become effective for the Company in future periods:

Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income

In February 2018, the FASB issued ASU 2018-02 to address the tax effects of the Tax Cuts & Jobs Act (“TCJA”) on amounts that were initially recognized directly in AOCI. ASU 2018-02 allows an entity to elect a one-time reclassification from AOCI to retained earnings of stranded tax effects due to the enactment of TCJA, equal to the difference between the amount initially charged or credited directly to AOCI at the previously enacted U.S. federal corporate income tax rate and the amount that would have been charged or credited directly to AOCI by using the newly enacted tax rate, excluding the effect of any valuation allowance previously charged to income from continuing operations. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company has evaluated the provisions of ASU 2018-02 and has determined it will not elect the reclassification from AOCI to retained earnings addressed in the ASU.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

Effects of the Tax Cuts and Jobs Act

In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (“SAB No. 118”) which allowed SEC registrants to record provisional amounts for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of TCJA. The Company recognized the estimated income tax effects of TCJA in its 2017 Consolidated Financial Statements in accordance with SAB No. 118. Refer to Note 7 for further information. The Company’s accounting for the TCJA one-time toll charge on previously undistributed accumulated foreign earnings has been completed, resulting in a $2,105 measurement period tax benefit and corresponding reduction in taxes payable. In accordance with SAB No. 118, any additional adjustment to the financial reporting impacts of TCJA will be completed by December 31, 2018.

Improvements to Nonemployee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07 which aligns the accounting for share-based payment awards issued to nonemployees with those issued to employees. Under the new guidance, the nonemployee awards will be measured on the grant date and compensation costs will be recognized when achievement of the performance condition is probable. This new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the new guidance and does not expect it to have a material impact on its consolidated financial statements.

Changes to the Disclosure Requirements for Fair Value Measurement

In August 2018, the FASB issued ASU 2018-13 which modifies the disclosure requirements for recurring and nonrecurring fair value measurements, primarily those surrounding Level 3 fair value measurements and transfers between Level 1 and Level 2. The new standard is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period. The Company is currently evaluating the new guidance and does not expect it to have an impact on its consolidated financial statements.

Changes to the Disclosure Requirements for Defined Benefit Plans

In August 2018, the FASB issued ASU 2018-14 which adds, modifies and removes certain disclosure requirements to improve the effectiveness of disclosures for defined benefit plans. The new standard is effective for fiscal years beginning after December 15, 2020, including interim periods within that reporting period. The Company is currently evaluating the new guidance and does not expect it to have an impact on its consolidated financial statements.

Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract

In August 2018, the FASB issued ASU 2018-15 which states entities should apply the guidance in ASC 350-40 when capitalizing implementation costs related to a hosting arrangement that is a service contract. The capitalized implementation costs should be classified as prepaid expenses and then expensed over the hosting arrangement’s term, with the expense recorded on the same line of the income statement as the service contract. The new standard is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period. The Company is currently assessing the impact that adopting this new accounting standard will have on its consolidated financial statements.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

Leases

In February 2016, the FASB issued ASU 2016-02 which requires lessees to recognize right of use assets and lease liabilities on the balance sheet for all leases with terms greater than twelve months. This standard is effective for fiscal years beginning after December 15, 2018, including interim periods within that reporting period. At this time, the Company has no significant financing leases and only a limited number of operating leases. The result of adoption will be an increase to assets and liabilities by the same amount for the identified operating leases. Several updates have been issued in 2018 that provide clarification on a number of specific issues and reporting requirements. The Company is currently evaluating the new guidance and does not expect the adjustment will be material to the Company, assuming there is not an increase in lease activity.

Simplifying the Test for Goodwill Impairment

In January 2017, the FASB issued ASU 2017-04 which simplifies the goodwill impairment test by eliminating Step 2 in the determination on whether goodwill should be considered impaired. Instead, an impairment charge should equal the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the amount of goodwill allocated to the reporting unit. The new standard is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period. The Company is currently evaluating the new guidance and does not expect it to have an impact on its consolidated financial statements.

~~Targeted Improvements to Accounting for Hedging Activities~~9

In August 2017, the FASB issued ASU 2017-12 which improves the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. The standard also makes certain targeted improvements to simplify the application of the hedge accounting guidance. The amendment is effective for fiscal years beginning after December 15, 2018, including interim periods within that reporting period. The Company is currently assessing the impact that adopting this new accounting standard will have on its consolidated financial statements.

(3) Revenue

In accordance with ASC 606, the Company disaggregates its revenue from customers with contracts by revenue streams. The Company’s revenue streams are presented in the following table:

	Three Months Ended		Nine Months Ended
	September 30, 2018		September 30, 2018
Single-use products	$	58,731	$	205,944
Multi-use products		39,037		168,310
Service revenue		6,463		16,321
Total gross sales	$	104,231	$	390,575

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

(3)

Revenue

In accordance with ASC 606, the Company disaggregates its revenue from customers with contracts by revenue streams. The Company’s revenue streams are presented in the following table:

	Three Months Ended March 31,
	2019		2018
Single-use products	$	62,265	$	72,778
Multi-use products		61,980		62,681
Service revenue		33,975		3,671
Total gross sales	$	158,220	$	139,130

Revenue is recognized when control over a product or service is transferred to a customer. Revenue is measured as the amount of consideration expected in exchange for transferring goods or providing services.

Sales terms to certain customers include rebates if certain conditions are met. Additionally, sales are generally made with a limited right of return under certain conditions. The Company estimates these rebates and returns at the time of sale based on the terms of agreements with customers and historical experience and estimated orders. The Company recognizes revenue net of these estimated costs which are classified as allowances and rebates.

The Company does not ~~disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The Company does not~~ have any unsatisfied performance obligations for contracts greater than one year. The costs incurred to obtain or fulfill a contract are not material.

For variable consideration arrangements where the transaction price fluctuates based on quantity, the most likely estimated quantity is assumed using forecasts provided by the customer.

Single-use products

In most single-use product sales, a quantity is ordered and manufactured according to the customer’s specifications and typically only one performance obligation is included. The Company also manufactures early phase product that can be included in a contract with services. These services are distinct and separated from the product performance obligations and are shown as a service revenue stream. The products are manufactured exclusively for a specific customer and have no alternative use. Generally, under these customer agreements, the Company is entitled to consideration for progress to date that includes an element of profit margin. To the extent an agreement does not include an element of profit margin for progress to date, it is recognized at a point in time. Revenues that are recognized over time utilize a measure of progress toward satisfaction of the performance obligations. The Company measures progress using an input method which compares the cost of cumulative work in process to date to the most current estimates for the entire performance obligation. The raw materials are excluded from this measurement due to the high value and inclusion in the early stages of the project that would otherwise overstate progress to date.

Multi-use products

The Company’s multi-use product sales can be sold to multiple customers and have an alternative use. Both the transaction sales price and shipping terms are agreed upon in the contract. For these products, all revenue is recognized at a point in time, generally when title to products and risk of loss is transferred to the customers based upon shipping terms. These arrangements typically include only one performance obligation.

~~Service revenue~~10

The service revenue stream represents services provided to a customer to assist with early stages of the regulatory approval process. The customer owns the drug details and process. The Company works with its customers to develop, validate and document the production process in order to comply with the regulatory approval process. These custom development projects could have one or more performance obligations with no alternative use. The contracts are structured to ensure the Company is paid for in-process work, including a profit margin. Revenues related to this stream are recognized over time by allocating to each performance obligation the best estimate of the standalone selling price of each service. The Company measures progress using an input method which compares the cost of cumulative work in process to date to the most current estimates for the entire performance obligation. Standalone selling prices are generally based on the prices charged to customers or based on an expected cost-plus margin.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

Service revenue

The service revenue stream represents services provided to a customer to assist with early stages of the regulatory approval process. The customer owns the drug details and process. The Company works with its customers to develop, validate and document the production process in order to comply with the regulatory approval process. These custom development projects could have one or more performance obligations with no alternative use. The contracts are structured to ensure the Company is paid for in-process work, including a profit margin. Revenues related to this stream are recognized over time by allocating to each performance obligation the best estimate of the standalone selling price of each service. Standalone selling prices are generally based on the prices charged to customers or based on an expected cost-plus margin. The Company measures progress using an input method which compares the cost of cumulative work in process to date to the most current estimates for the entire performance obligation.

Contract balances

The timing of revenue recognition, billings and cash collections results in billed trade receivables, ~~contracts~~contract assets (unbilled receivables), and contract liabilities (customer advances and deferred revenue). For each reporting period presented, the Company reports contract balances in a net contract asset or liability position on a contract-by-contract basis. Contract assets are recorded when the right to consideration is conditioned on something other than the passage of time. When an entity’s right to consideration is unconditional, the receivable is recorded within Trade Receivables on the balance sheet. Contract liabilities represent advance payments from customers, and deferred revenue. Contract assets will convert to trade receivables or cash and current contract liabilities will convert into revenue within a one-year period.

Payment terms can vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, payment prior to satisfaction of a performance obligation can be required, and results in recording a contract liability.

The following table details the significant changes in contract assets ~~during the nine months ended September 30, 2018~~:

	Contract Assets
	2019			2018
Balance as of January 1, 2018	$	51,896
Balance as of January 1,	$	33,490		$	51,896
Contracts assets acquired		3,749
Contract assets acquired		4,243			-
Revenue recognized from performance obligations satisfied		~~201~~70,~~210~~408			72,031
Transferred to trade receivables		(~~143~~31,~~094~~578	)		(34,751	)
Currency impact		(~~916~~494	)		(186	)
Balance as of September 30, 2018	$	112,845
Balance as of March 31,	$	76,069		$	88,990

The Company recognized in revenue $12,~~116~~543 and $808, during the ~~nine~~three months ended ~~September 30~~March 31, 2019 and 2018, respectively, for which the contract liability was recorded in a prior period.

(4)	Acquisitions

On ~~September~~January 122, ~~2018~~2019, the Company completed the acquisition of 100% of ~~Halo~~Avista Pharma Solutions (“~~Halo~~Avista”), a ~~finished~~contract ~~dosage~~development, ~~form~~manufacturing, ~~Contract~~and ~~Development~~testing ~~and~~organization ~~Manufacturing~~with ~~Organization.~~sites ~~The~~located ~~deal~~in ~~was~~Durham, ~~structured~~NC, asLongmont, aCO, ~~stock~~Agawam, ~~purchase~~MA ~~for~~and ~~consideration~~Edinburgh, Scotland U.K. The purchase price of $~~425~~252,000~~. The~~ ~~Company~~was ~~utilized~~funded with a combination of cash on hand and borrowings under the credit facility ~~to pay the purchase price~~. ~~Cambrex~~ ~~acquired~~See ~~two~~Note ~~GMP~~8 ~~compliant~~for ~~facilities,~~details ~~one~~on ~~in Whippany, NJ,~~ the ~~other~~amended inand ~~Mirabel,~~restated ~~Quebec~~credit facility.

The addition of Halo adds formulation development and finished dosage manufacturing capabilities to the Company’s existing global API manufacturing network. These newly acquired facilities provide formulation development and clinical and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. The facilities core competencies include developing and manufacturing highly complex and difficult to produce formulations, products for pediatric indications and controlled substances.11

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

Avista offers a broad suite of scientifically differentiated services ranging from early stage API and drug product development and cGMP manufacturing to stand-alone analytical, microbiology testing and solid state sciences.

The following table summarizes the estimated fair value of the assets acquired and liabilities assumed at the acquisition date. Cambrex is in the process of obtaining third-party valuations of certain tangible and intangible assets; thus the provisional measurements of property, plant and equipment, intangible assets, goodwill and deferred income taxes are subject to change.

	September 12, 2018
	January 2, 2019
Cash	$	24,~~792~~125
Account receivable and Contract assets		14,045
Trade receivables		6,786
Inventory		8,298
Contract assets		4,243
Other current assets		1,110
Inventories		21
Property, plant and equipment		78,364
Other current assets		1,159
Goodwill		228,504
Property, plant and equipment		34,172
Intangible assets		180,000
Right of use assets		31,497
Total assets acquired		513,113
Goodwill		148,481
Current liabilities		16,058
Intangible assets (Customer relationships)		73,000
Noncurrent liabilities		69,666
Other non-current assets		532
Total liabilities assumed	$	85,724
Total assets acquired		304,016
Operating lease liabilities, current		2,053
Other current liabilities		11,422
Operating lease liabilities, non-current		29,444
Other non-current liabilities		8,826
Total liabilities assumed	$	51,745

Transaction costs have been ~~expensed~~recorded as “Acquisition and integration expenses” on the Company’s income statement and totaled $63,~~460~~771 for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2018~~2019. ~~These~~Other ~~costs~~acquisition and integration related expenses of $2,285 for the three months ended March 31, 2019 have also been recorded to “Acquisition and integration expenses” on the Company’s income statement.

The consolidated income statement ~~from~~for the ~~acquisition~~three ~~date~~months ~~to the period~~ ending ~~September~~March 3031, ~~2018~~2019 ~~included~~includes revenue from Avista of $517,~~154~~172, and a net ~~income~~loss of $861,740. These results include integration costs of $~~394~~1,206, primarily consisting of a one-time charge for severance.

~~(5)~~On ~~Net~~September ~~Inventories~~12, 2018, the Company completed the acquisition of 100% of Halo Pharma, a finished dosage form contract development and manufacturing organization. During the three months ended March 31, 2019, the opening balance sheet was adjusted to reflect a change in the valuation of property, plant and equipment resulting in a decrease in goodwill of $1,940.

~~Inventories are stated at the lower of cost and net realizable value. Cost is determined on a first-in, first-out basis.~~12

Net inventories consist of the following:

	September 30, 2018		December 31, 2017
Finished goods	$	26,016	$	41,521
Work in process		23,076		47,386
Raw materials		46,666		42,491
Supplies		7,890		7,144
Total	$	103,648	$	138,542

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

(5)	Net Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined on a first-in, first-out basis.

Net inventories consist of the following:

	March 31, 2019		December 31, 2018
Finished goods	$	26,349	$	30,904
Work in process		37,262		27,513
Raw materials		47,998		44,705
Supplies		7,921		7,940
Total	$	119,530	$	111,062

(6)	Goodwill and Intangible Assets

The ~~change~~changes in the carrying amount of goodwill for the ~~nine~~three months ended ~~September 30,~~March ~~2018~~31, is2019 are as follows:

Balance as of December 31, 2017	$	43,626
Balance as of December 31, 2018	$	261,095
Acquisition of business (see Note 4)		~~228~~146,~~504~~541
Translation effect		(~~706~~124	)
Balance as of September 30, 2018	$	271,424
Balance as of March 31, 2019	$	407,512

As of ~~September~~March 3031, ~~2018~~2019, goodwill of $~~228~~217,~~747~~130 relates to the ~~FDF~~DP segment and $157,527 relates to the ESDT segment. The remaining goodwill relates to the ~~API~~DS segment.

Acquired intangible assets, which are amortized, consist of the following:

As of September 30, 2018

As of March 31, 2019

Amortization Period

Gross Carrying Amount

Accumulated Amortization

Net Carrying Amount

Internal-use software

3 - 7 years

7,~~034~~553

(23,~~636~~194

)

4,~~398~~359

Technology-based intangibles

20 years

3,~~519~~415

(1,~~496~~536

)

21,~~023~~879

Customer-related intangibles

10 - 15 years

~~187~~260,~~942~~229

(29,~~404~~963

)

~~185~~250,~~538~~266

~~198~~271,~~495~~197

(614,~~536~~693

)

~~191~~256,~~959~~504

As of December 31, 2017

As of December 31, 2018

Amortization Period

Gross Carrying Amount

Accumulated Amortization

Net Carrying Amount

Internal-use software

3 - 7 years

7,~~074~~026

(12,~~810~~912

)

54,~~264~~114

Technology-based intangibles

20 years

3,~~646~~481

(1,~~413~~523

)

21,~~233~~958

Customer-related intangibles

10 - 15 years

7186,~~608~~698

(15,~~237~~565

)

6181,~~371~~133

18197,~~328~~205

(410,~~460~~000

)

13187,~~868~~205

The change in the gross carrying amount in 2018 is mainly due to the provisional recognition of customer-related intangibles of $180,000 due to the acquisition of Halo Pharma in September 2018 and the impact of foreign currency translation. The change in the gross carrying amount in 2017 is mainly due to foreign currency translation and additions. 13

Amortization expense was $1,134 and $2,157 for the three and nine months ended September 30, 2018, respectively. This includes amortization expense of $627 related to the acquisition of Halo Pharma. Amortization expense was $477 and $1,375 for the three and nine months ended September 30, 2017, respectively.

Amortization expense related to intangible assets is expected to be approximately $5,043 for 2018, $14,053 for 2019, $14,037 for 2020, $14,031 for 2021, and $13,610 for 2022.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

The change in the gross carrying amount in 2019 is mainly due to the recognition of customer-related intangibles of $73,000 from the acquisition of Avista in January 2019, the impact of foreign currency translation and additions to internal-use software.

Amortization expense was $4,730 and $513 for the three months ended March 31, 2019 and 2018, respectively. This includes amortization expense of $2,996 related to the acquisition of Halo and $1,217 related to the acquisition of Avista.

Amortization expense related to intangible assets is expected to be approximately $18,911 for 2019, $18,894 for 2020, $18,888 for 2021, $18,449 for 2022, and $17,835 for 2023.

(7)	Income Taxes

Income tax ~~benefit~~expense from continuing operations for the three ~~and nine~~ months ended ~~September 30~~March 31, 2019 and 2018 was $153,~~406~~532 and $~~872~~5,786, respectively,. ~~compared~~The toeffective ~~expense~~tax ofrate ~~$7,498 and $22,484~~ for the three ~~and nine~~ months ended ~~September 30,~~March ~~2017~~31, ~~respectively. The~~2019 ~~Company’s~~and ~~provisional~~2018 ~~accounting~~was ~~for~~25.1% ~~TCJA’s~~and ~~toll~~19.3%, ~~charge~~respectively. onIncome ~~previously~~tax ~~undistributed~~expense ~~accumulated~~for ~~foreign~~the ~~earnings~~three atmonths ~~December~~ended March 31, ~~2017~~2018 ~~has~~would have been ~~completed~~19.8% inexcluding the ~~period~~impact ~~ending~~of ~~September~~certain ~~30,~~effects ~~2018,~~of ~~resulting~~share-based incompensation. aThe ~~$2,105~~increase ~~measurement~~in ~~period~~the tax ~~benefit. In~~rate ~~accordance~~for ~~with~~2019 ~~SAB~~as ~~No.~~compared ~~118,~~to ~~any~~2018 ~~additional~~is ~~adjustment~~primarily due to state tax reform and the ~~financial~~Company’s ~~reporting~~expanded ~~impacts~~state ofpresence ~~TCJA~~due ~~will~~to bethe ~~completed~~Halo byand ~~December~~Avista 31acquisitions, ~~2018.~~and the geographic mix of income.

The income tax benefit for the three and nine months ended September 30, 2018 includes the impacts of immediately recognizing certain effects of share-based compensation, acquisition and integration expenses, unrealized gain on investment in equity securities, and benefits for finalizing the TCJA toll charge and New Jersey tax reform. Excluding these items, the effective tax rate would have been 19.6% and 20.5% for the three and nine months ended September 30, 2018, respectively, compared to 33.2% and 32.1% for the three and nine months ended September 30, 2017, respectively.

The Company has determined it will elect the accounting policy to treat tax on global intangible low-taxed income (“GILTI”) inclusions under TCJA as a component of current tax expense in its estimated annual effective tax rate. This accounting policy election is now complete.

In July 2018, New Jersey enacted comprehensive corporate income tax reform legislation which includes, among other items, the imposition of a multi-year temporary surtax, mandatory combined reporting, revised net operating loss (“NOL”) and dividend exclusion rules, and decoupling from certain federal tax reform provisions. Additionally, in October 2018 New Jersey enacted legislation that included significant technical corrections and clarifications to the July law as well as other substantive changes to the State’s corporate tax regime. GAAP requires that the effects of a change in tax law be recorded in the period of enactment. Therefore, the Company has included the effects of New Jersey’s July tax law change in the results for the quarter ended September 30, 2018. This includes a discrete benefit of $11,437 to release valuation allowance against state NOLs and state net deferred tax assets against which the Company had previously maintained a full valuation allowance due to restrictive rules regarding realization, and a discrete benefit of $752 for revaluing state tax attributes and net deferred tax assets due to the New Jersey surtax. The Company currently estimates it will record a non-cash charge of approximately $1,600 in the quarter ended December 31, 2018 due to New Jersey’s October tax law change.

The Company considers both positive and negative evidence related to the likelihood of realization of deferred tax assets. If, based on the weight of available evidence, it is more likely than not the deferred tax assets will not be realized, the Company records a valuation allowance against all or a portion of the deferred tax assets to adjust the balance to the amount considered more likely than not to be realized. The weight given to the positive and negative evidence is commensurate with the extent to which the evidence may be objectively verified.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

This assessment, which is completed on a taxing jurisdiction basis, takes into account a number of types of evidence, including the following:

•Nature, frequency, and severity of current and cumulative financial reporting losses. A pattern of objectively-measured recent financial reporting losses is heavily weighted as a source of negative evidence. The Company generally considers cumulative pre-tax losses in the current three-year period to be significant negative evidence regarding future profitability. The Company also considers the strength and trend of earnings, as well as other relevant factors. In certain circumstances, historical information may not be as relevant due to changes in the Company’s business operations;

•Sources of future taxable income. Future reversals of existing taxable temporary differences are heavily-weighted sources of objectively verifiable evidence. Projections of future taxable income exclusive of reversing temporary differences are a source of positive evidence only when the projections are combined with a history of recent profits and can be reasonably estimated; and

•Tax planning strategies. Prudent and feasible tax planning strategies that would be implemented to maximize utilization of expiring tax credit carryforwards are evaluated as a source of additional positive evidence.

New Jersey’s change to combined reporting will allow the Company to use existing state NOLs to offset a portion of the Company’s combined domestic income that will be taxed by New Jersey. On a New Jersey combined basis the Company has significant existing taxable temporary differences along with a sustained period of profitability and expectations of future profitability of sufficient amounts, therefore the Company has reversed its valuation allowance against certain state NOLs and state net deferred tax assets in the quarter ended September 31, 2018.

(8)	Long-term Debt

InOn ~~May~~January ~~2016~~2, 2019, the Company ~~entered~~amended and restated its Credit Facility by entering into aan $~~500~~800,000 five-year Syndicated Senior ~~Revolving~~ Credit Facility (“Credit Facility”), ~~which~~comprising ~~expires~~of ina ~~May~~$600,000 ~~2021~~Revolving Credit Facility and $200,000 Term Loan A. The Company is required to make minimum quarterly principal payments on the Term Loan A of $2,500 through December 2020, $3,750 through December 2022 and $5,000 through December 2023. The remainder of the principal is due on January 2, 2024. The Company pays interest on ~~this~~the Credit Facility at LIBOR plus 1.25% - 2.00% based upon certain financial measurements. The Credit Facility also includes financial covenants regarding interest coverage and leverage ratios. The Company was in compliance with all financial covenants at ~~September~~March 3031, ~~2018~~2019 and December 31, ~~2017~~2018. As of ~~September~~March 3031, ~~2018~~2019, there was $~~325~~497,~~000~~500 outstanding on the Credit Facility, of which $10,000 was recorded as current in the consolidated balance sheet. As of December 31, ~~2017~~2018, ~~the~~there ~~facility~~ was ~~undrawn~~$300,000 outstanding on the Credit Facility. The ~~2018~~2019 weighted average interest rate for long-term bank debt was 34.63%.

(9)	Derivatives

The Company operates internationally and is exposed to fluctuations in foreign exchange rates and interest rates in the normal course of business. The Company, from time to time, uses derivatives to reduce exposure to market risks resulting from fluctuations in interest rates and foreign exchange rates.

All financial instruments involve market and credit risks. The Company is exposed to credit losses in the event of non-performance by the counterparties to the contracts. While there can be no assurance, the Company does not anticipate non-performance by these counterparties.

Foreign Currency Forward Contracts

The Company periodically enters into foreign currency forward contracts to protect against currency fluctuations of forecasted cash flows and existing balance sheet exposures at its foreign operations, as deemed appropriate. The Company may or may not elect to designate certain forward contracts for hedge accounting treatment.

1814

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

For derivatives that are not designated for hedge accounting treatment, changes in the fair value are immediately recognized in earnings. This treatment has the potential to increase volatility of the Company’s earnings.

None of the foreign currency forward contracts entered into during the ~~nine~~three months ended ~~September 30~~March 31, ~~2018~~2019 and ~~2017~~2018 were designated for hedge accounting treatment. The notional amounts of the Company’s outstanding foreign exchange forward contracts were $6355,~~918~~765 and $3235,~~781~~734 at ~~September 30~~March 31, ~~2018~~2019 and December 31, ~~2017~~2018, respectively. The Company does not hold or purchase any foreign currency forward contracts for trading or speculative purposes and no contractual term is greater than twelve months.

The fair value of the Company’s foreign exchange forward contracts outstanding was a gain of $~~1,582~~562 and a loss of $83430 at ~~September 30~~March 31, ~~2018~~2019 and December 31, ~~2017~~2018, respectively. Losses are ~~recorded~~reflected inunder the caption “Accrued expenses and other current liabilities” and gains are ~~recorded~~reflected inunder the caption “Prepaid expenses and other current assets” on the Company’s balance sheet and “Other revenues, net” on the Company’s income statement.

Interest Rate Swap

The Company entered into an interest rate swap in February 2019 to reduce the impact of changes in interest rates on its floating rate debt through February 2023. The swap is a contract to exchange floating rate for fixed interest payments periodically over the life of the agreement without the exchange of the underlying notional debt amount.

The swap contract outstanding at March 31, 2019 has been designated as a cash flow hedge and, accordingly, changes in the fair value of this derivative are not recorded in earnings but are recorded each period in AOCI and reclassified into earnings as interest expense in the same period during which the hedged transaction affects earnings. The ineffective portion of the interest rate swap is recognized in earnings and has been immaterial to the Company's financial results.

As of March 31, 2019, the interest rate swap had a notional value of $200,000, at a fixed rate of 2.54%. The fair value of this swap is based on quoted market prices and was in a loss position of $2,775 at March 31, 2019. The Company did not have an interest rate swap outstanding at December 31, 2018. Losses are reflected in the Company’s balance sheet under the caption “Accrued expenses and other current liabilities.”

At March 31, 2019, the Company’s interest rate swap fixed 41% of the variable interest rate debt. Holding all other variables constant, if the LIBOR portion of the weighted average interest rate in the variable debt increased by 100 basis points, the effect on the Company would have been higher interest expense of $2,875.

Assuming current market conditions continue, a loss of $307 is expected to be reclassed out of AOCI into earnings within the next twelve months.

(10)	Fair Value Measurements

Accounting standards establish a valuation hierarchy for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation; Level 3 inputs are unobservable inputs based on the Company’s assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

~~The following table provides the assets carried at fair value, measured on a recurring basis, as of September 30, 2018 and December 31, 2017:~~15

Fair Value - Level 2	September 30, 2018		December 31, 2017
Foreign currency forwards	$	1,582	$	83
Investment in equity securities		10,825		-
	$	12,407	$	83

The Company’s foreign currency forward contracts are measured at fair value using observable market inputs such as forward rates, the Company’s credit risk and its counterparties’ credit risks. Based on the Company’s continued ability to enter into forward contracts, the Company considers the markets for its fair value instruments to be active.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

~~marketability~~The tofollowing betable ~~applied~~provides to the ~~closing~~assets ~~market~~and ~~price~~liabilities ofcarried ~~the~~at ~~shares as of September 30, 2018. The~~ fair value ~~of the Company’s shares increased to $10~~,~~825~~ ~~during~~measured ~~the~~on ~~nine~~a ~~months~~recurring ~~ended September 30~~basis, ~~2018 resulting in an unrealized gain that was recorded~~ as ~~“Unrealized gain on investment in equity securities” on the income statement. Since the shares owned by the Company are substantially in excess~~ of ~~the~~March ~~daily trade volumes of the stock~~31, it2019 ~~could be difficult to sell the shares in a timely manner when the restrictions lapse~~ and itDecember is31, ~~possible the ultimate value to be realized by the Company could be significantly less upon a sale of the securities.~~2018:

Fair Value - Level 2	March 31, 2019			December 31, 2018
Interest rate swap, liability	$	(2,775	)	$	-
Foreign currency forwards, assets/(liabilities)		562			(430	)
Investment in equity securities, asset		12,055			13,048
	$	9,842		$	12,618

The fair value of the interest rate swap is estimated based on the present value of the difference between expected cash flows calculated at the contracted interest rate and the expected cash flows at current market interest rates using observable benchmarks for the LIBOR forward rates at the end of the period. The Company’s credit risk and its counterparty’s credit risk is also evaluated to estimate fair value.

As of the second quarter of 2018, the Company owns a 16.3% equity investment in a European company. In accordance with ASC 825, the Company has elected to record this investment at fair value. The Company selected an appropriate valuation methodology to compute a discount for the lack of marketability to be applied to the closing market price of the shares as of March 31, 2019. The fair value of the Company’s shares decreased to $12,055 during the three months ended March 31, 2019 resulting in an unrealized loss of $569 which was recorded as “Unrealized loss on investment in equity securities” on the income statement and “Prepaid expenses and other current assets” on the balance sheet. Since the shares owned by the Company are substantially in excess of the daily trade volumes of the stock, it could be difficult to sell the shares in a timely manner when the restrictions lapse in the second quarter of 2019 and it is possible the ultimate value to be realized by the Company could be significantly less upon a sale of the securities.

The Company’s financial instruments also include cash and cash equivalents, accounts receivables and accounts payables. The carrying amount of these instruments approximates fair value because of their short-term nature.

(11) ~~Accumulated Other Comprehensive Income/(Loss)~~Leases

~~The~~In ~~following~~February ~~tables~~2016 ~~provide~~ the ~~changes~~FASB inissued ~~Accumulated~~ASU ~~other~~2016-02, ~~comprehensive~~Leases ~~income~~ (“~~AOCI~~ASC 842”), bywhich ~~component~~requires ~~(pension,~~lessees ~~net~~to recognize right of ~~tax~~use (“ROU”) assets and lease liabilities on the balance sheet for all leases with terms greater than twelve months. Lease obligations are measured at the ~~three~~present value of remaining lease payments and ~~nine~~accounted ~~months~~for ~~ended~~using ~~September 30~~the effective interest method. Leases will be classified as finance or operating, ~~2018~~with classification affecting the pattern and ~~2017:~~expense recognition in the income statement.

	Foreign Currency Translation Adjustments			Pension Plans			Total
Balance as of June 30, 2018	$	(22,576	)	$	(29,687	)	$	(52,263	)
Other comprehensive income before reclassifications		32			-			32
Amounts reclassified from accumulated other comprehensive loss		-			202			202
Net current-period other comprehensive income		32			202			234
Balance as of September 30, 2018	$	(22,544	)	$	(29,485	)	$	(52,029	)
	Foreign Currency Translation Adjustments			Pension Plans			Total
Balance as of June 30, 2017	$	(21,543	)	$	(30,743	)	$	(52,286	)
Other comprehensive income before reclassifications		7,006			-			7,006
Amounts reclassified from accumulated other comprehensive loss		-			250			250
Net current-period other comprehensive income		7,006			250			7,256
Balance as of September 30, 2017	$	(14,537	)	$	(30,493	)	$	(45,030	)

The Company adopted the new lease standard on January 1, 2019 by applying the new transition alternative. As such, the Company initially applied the new standard to all leases existing at the beginning of the period of adoption. Prior period financial results were not updated and the disclosures required under the new standard were not provided for dates and periods before January 1, 2019.

2016

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

	Foreign Currency Translation Adjustments			Pension Plans			Total
Balance as of December 31, 2017	$	(12,040	)	$	(30,188	)	$	(42,228	)
Other comprehensive loss before reclassifications		(10,504	)		-			(10,504	)
Amounts reclassified from accumulated other comprehensive loss		-			703			703
Net current-period other comprehensive (loss)/income		(10,504	)		703			(9,801	)
Balance as of September 30, 2018	$	(22,544	)	$	(29,485	)	$	(52,029	)
	Foreign Currency Translation Adjustments			Pension Plans			Total
Balance as of December 31, 2016	$	(34,290	)	$	(31,230	)	$	(65,520	)
Other comprehensive income before reclassifications		19,753			-			19,753
Amounts reclassified from accumulated other comprehensive loss		-			737			737
Net current-period other comprehensive income		19,753			737			20,490
Balance as of September 30, 2017	$	(14,537	)	$	(30,493	)	$	(45,030	)

The new standard provides a number of optional practical expedients in transition. The Company has elected the package of practical expedients permitted under the transition guidance within the new standard, that allows the Company (1) to not reassess whether any expired or existing contracts are or contain leases, (2) to not reassess the lease classification for any expired or existing leases, and (3) to not reassess initial direct costs for any existing leases. The Company has also elected, for its vehicle and equipment leases, the practical expedient that permits the ability to choose not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component.

21Further, the Company has made an accounting policy election to keep leases with an initial term of twelve months or less off the balance sheet. This policy applies to all classes of the underlying assets. The Company will recognize those lease payments in the consolidated income statement over the lease term.

The determination of the incremental borrowing rate used to calculate the present value of the ROU assets and lease liabilities depends on whether an interest rate is specified in the lease or not. If the lease specifies a rate, that rate is used when calculating the present value of lease payments. If the rate is not readily determinable, which is generally the case for the Company, the Company’s incremental borrowing rate (“IBR”) as of the date of inception is used (for initial measurement, the IBR was determined as of the adoption date of the standard). The incremental borrowing rate is the estimated rate of interest that Cambrex would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.

The Company’s leases that contain variable payments are not material.

Operating Leases:

The Company has operating leases expiring on various dates through the year 2032 with options to extend beyond this date. The leases are primarily for the rental of manufacturing, office and warehouse space in addition to vehicles, forklifts and equipment. The Company generally enters into operating leases when it doesn’t have the desire to own the asset.

The Company’s operating leases related to the rental of manufacturing, office and warehouse space often contain one or more options to extend the lease, typically for a period of three to five years each and based on the then prevailing market rental rate. The Company will generally exercise these options to extend the lease for its manufacturing space due to the significant costs to install and remove the manufacturing equipment should the Company decide to vacate the building. As such, the lease terms used in calculating the value of the ROU assets and lease liabilities for these types of leases will include the periods covered under any renewal options.

The Company’s equipment, vehicle and forklift leases may or may not contain an option to extend the lease but as a general rule, the Company doesn’t exercise these options because there are no associated costs to return the equipment and either purchase or lease new equipment. As a result, these extension options aren’t considered in the calculation of ROU assets and lease liabilities. If or when circumstances change and the Company becomes reasonably certain that it is going to exercise the extension option, the ROU asset and lease liability would be remeasured at that time.

For operating leases, the depreciation and interest expense components are combined and recognized evenly over the term of the lease as cost of goods sold and selling, general and administrative expense in the Company’s income statement.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

~~The~~As ~~following~~of ~~tables~~March ~~provide~~31, ~~the~~2019, ~~reclassifications~~ROU ~~from~~assets ~~AOCI~~related byto ~~component~~operating ~~for~~leases were $37,260 and reflected in the ~~three~~Company’s balance sheet under the caption “Right of use assets.” As of March 31, 2019, short-term operating lease liabilities were $2,709 and ~~nine~~reflected ~~months~~in ~~ended~~the ~~September 30~~Company’s balance sheet under the caption “Operating lease liabilities, ~~2018~~current” and ~~2017:~~long-term operating lease liabilities were $34,658 and reflected in the Company’s balance sheet under the caption “Operating lease liabilities, non-current.”

Details about AOCI Components	Three Months Ended September 30, 2018			Nine Months Ended September 30, 2018
Amortization of defined benefit pension items:
Actuarial losses	$	(273	)	$	(953	)
Prior service credit		2			4
Total before tax		(271	)		(949	)
Tax benefit		69			246
Net of tax	$	(202	)	$	(703	)
Total reclassification for the period	$	(202	)	$	(703	)
Details about AOCI Components	Three Months Ended September 30, 2017			Nine Months Ended September 30, 2017
Amortization of defined benefit pension items:
Actuarial losses	$	(355	)	$	(1,048	)
Prior service costs		(13	)		(39	)
Total before tax		(368	)		(1,087	)
Tax benefit		118			350
Net of tax	$	(250	)	$	(737	)
Total reclassification for the period	$	(250	)	$	(737	)

The Company’s largest leases are described below:

The Company ~~recognizes~~leases ~~all~~its ~~components~~manufacturing ofand ~~net~~office ~~periodic~~facilities ~~benefit~~in ~~cost~~Longmont, ~~except~~Colorado, ~~service~~where ~~costs~~it inprovides ~~“Other~~services ~~expenses,~~required ~~net”~~to inadvance ~~its~~a ~~income~~new ~~statement.~~molecule ~~Service~~to ~~costs~~the ~~are~~clinic ~~recognized~~including inprocess ~~“Selling~~development, ~~general~~analytical development, API manufacturing, stability and ~~administrative~~packaging, ~~expenses”~~labeling and ~~“Cost~~shipping. This facility is part of ~~goods~~the ~~sold”~~ESDT segment. The lease expires in ~~its~~May ~~income~~2025 ~~statement~~and ~~depending~~includes ontwo ~~the~~five ~~functional~~year ~~area~~extension ofoptions ~~the~~at ~~underlying~~prevailing ~~employees~~market ~~included~~rates. inRent ~~the~~expense ~~plan~~is recognized on a straight-line basis and is approximately $1,700 per year.

~~(12)~~The ~~Stock~~Company ~~Based~~leases ~~Compensation~~its manufacturing and office facilities in Durham, North Carolina, where it performs analytical development & testing, process chemistry and API manufacturing and is part of the ESDT segment. The lease expires in March 2023 and includes one five year extension option at prevailing market rates. Rent expense is recognized on a straight-line basis and is approximately $1,300 per year.

The Company ~~recognizes~~leases ~~compensation~~office ~~costs~~space ~~for~~in ~~stock~~East ~~options~~Rutherford, ~~awarded~~New toJersey ~~employees~~for ~~based~~its oncorporate ~~their grant-date fair value~~headquarters. The ~~value~~lease ofexpires ~~each~~in ~~stock~~November ~~option~~2029. isThis ~~estimated~~lease onincludes ~~the~~one ~~date~~five ofyear ~~grant~~extension ~~using the Black-Scholes~~ option~~-pricing~~ ~~model. The~~at ~~weighted-average~~prevailing ~~fair~~market ~~value~~rates ~~per~~but ~~share~~at ~~for~~this time, the ~~stock~~expiration ~~options~~date ~~granted~~is totoo ~~employees~~far ~~during~~in the ~~nine~~future ~~months~~to ~~ended~~be ~~September 30,~~reasonably ~~2018~~certain ~~was~~that ~~$24.54.~~the ~~The~~lease ~~weighted-average~~will ~~fair~~be ~~value~~extended. ~~per~~Rent ~~share~~expense ~~for~~is ~~the~~recognized ~~stock~~on ~~options~~a ~~granted~~straight-line tobasis ~~employees~~and ~~during~~is ~~the~~approximately ~~nine~~$400 ~~months~~per ~~ended September 30, 2017 was $20~~year.~~14.~~

22Finance leases:

The Company has finance leases expiring on various dates through the year 2023. The leases are primarily for the rental of manufacturing equipment. These leased assets are amortized on a straight-line basis and recorded as depreciation expense and the financing component is recorded as interest expense in the income statement resulting in higher expense in the earlier part of the lease term.

For finance leases, the depreciation expense is recognized evenly over the term of the lease as cost of goods sold and selling, general and administrative expense in the Company’s income statement. The interest expense component is recognized separately as interest expense in the Company’s income statement.

As of March 31, 2019, ROU assets related to finance leases were $3,617 and reflected in the Company’s balance sheet under the caption “Property, plant and equipment, net.” As of March 31, 2019, short-term finance lease liabilities were $1,077 and reflected in the Company’s balance sheet under the caption “Accrued expenses and other current liabilities” and long-term finance lease liabilities were $1,424 and reflected in the Company’s balance sheet under the caption “Other non-current liabilities.”

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

~~For~~The ~~the~~following ~~three~~table ~~months~~summarizes ~~ended September 30, 2018 and 2017,~~ the ~~Company~~lease ~~recorded~~activity ~~$994 and $1,187, respectively, in “Selling, general and administrative expenses”~~ for ~~stock options. For~~ the ~~nine~~three months ended ~~September 30,~~March ~~2018 and 2017~~31, the Company recorded $3,182 and $3,313, respectively, in “Selling, general and administrative expenses” for stock options. As of September 30, 2018, the total compensation cost related to unvested stock options not yet recognized was $6,466. The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of 1.9 years.2019:

The following table is a summary of the Company’s stock options:

	Three Months Ended March 31, 2019
Lease cost:
Operating lease cost	$	1,186
Finance lease cost
Amortization of ROU assets		72
Interest on lease liabilities		47
Short-term lease cost		217
Total lease cost		1,522

Options		Number of Shares			Weighted Average Exercise Price
Other Information:
Outstanding at December 31, 2017			1,484,914		$	32.53
Operating cash flows from operating leases		(1,067	)
Exercised			(112,669	)		24.16
Operating cash flows from finance leases		(13	)
Forfeited or expired			(5,311	)		36.94
Financing cash flows from finance leases	$	(276	)
Outstanding at March 31, 2018			1,366,934			33.20
Weighted-average remaining lease term - operating leases (yrs)		10.4
Granted			14,265			53.70
Weighted-average remaining lease term - finance leases (yrs)		3.0
Exercised			(93,500	)		20.07
Weighted-average discount rate - operating leases		4.2	%
Forfeited or expired			(6,759	)		35.06
Weighted-average discount rate - finance leases		4.1	%
Outstanding at June 30, 2018			1,280,940			34.38
Exercised			(336,805	)		24.01
Forfeited or expired			(53,527	)		50.18
Outstanding at September 30, 2018			890,608			37.35
Exercisable at September 30, 2018			207,791		$	30.20

The ~~aggregate~~following ~~intrinsic~~table ~~values~~represents ~~for~~the ~~all~~Company’s ~~stock~~undiscounted ~~options~~lease ~~exercised~~maturities ~~for~~over the ~~three~~next ~~and~~five ~~nine~~years ~~months ended September 30, 2018 were $12,685~~ and ~~$18,494,~~beyond ~~respectively. The aggregate intrinsic values~~ for ~~all~~its ~~stock~~operating ~~options exercised for the three~~ and ~~nine~~finance ~~months~~leases. ~~ended~~The ~~September 30,~~undiscounted ~~2017~~cash ~~were~~flows ~~$2,669~~disclosed ~~and~~below ~~$12,011,~~represent ~~respectively. The~~full ~~aggregate~~years ~~intrinsic values~~ for all ~~stock~~periods ~~options outstanding and exercisable as of September 30, 2018 were $27,656 and $7,937, respectively~~presented.

23Below is a reconciliation of the Company’s undiscounted cash flows to the operating and finance lease liabilities recognized in the consolidated balance sheet.

	Total Undiscounted Cash Flows
	Operating Leases		Finance Leases
2019	$	4,769	$	1,126
2020		5,114		1,033
2021		5,038		596
2022		4,966		201
2023		4,971		43
2024+		26,432		-
		51,290		2,999

Present values ("PV"):
Lease liabilities, current		2,709		1,077
Lease liabilities, non-current		34,658		1,424
Total PV of lease liabilities		37,367		2,501
Difference between undiscounted cash flows and discounted cash flows	$	13,923	$	498

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

~~The~~At ~~following~~December ~~table~~31, is2018, athe ~~summary~~Company ofhad ~~the~~operating ~~Company’s~~leases ~~unvested~~expiring ~~stock~~on ~~options,~~various ~~restricted~~dates ~~stock~~through ~~and~~the ~~performance~~year ~~shares~~2029. ~~for~~The ~~which~~leases ~~the~~were ~~requisite~~primarily ~~service~~for ~~period~~the ~~has~~rental ~~not~~of ~~been~~office ~~rendered~~space. ~~but~~At ~~that~~December ~~are~~31, ~~expected~~2018, tofuture ~~vest~~minimum oncommitments ~~the~~under ~~achievement~~non-cancelable ofoperating alease ~~performance~~arrangements ~~condition~~were as follows:

	Unvested Stock Options					Unvested Restricted Stock					Unvested Performance Shares
	Total Undiscounted Cash Flows
	Number of Shares			Weighted- Average Grant-Date Fair Value		Number of Shares			Weighted- Average Grant-Date Fair Value		Number of Shares			Weighted- Average Grant-Date Fair Value
2019	$	1,004
Unvested at December 31, 2017		757,269		$	15.20		265		$	44.23		276,250		$	42.08
2020		1,204
Vested during period		(21,510	)		13.99		-			-		-			-
2021		1,126
Forfeited		(5,311	)		13.90		-			-		(17,250	)		40.65
2022		974
Unvested at March 31, 2018		730,448			15.25		265			44.23		259,000			42.17
2023		937
Granted		14,265			24.54		9,779			53.70		17,250			40.65
2024+		3,220
Vested during period		(1,610	)		17.34		(265	)		44.23		-			-
	$	8,465
Forfeited		(6,759	)		13.27		-			-		(28,750	)		41.36
Unvested at June 30, 2018		736,344			15.44		9,779			53.70		247,500			42.16
Forfeited		(53,527	)		19.27		-			-		(42,250	)		42.53
Unvested at September 30, 2018		682,817		$	15.14		9,779		$	53.70		205,250		$	42.08

~~For~~The ~~the~~difference ~~three~~between ~~months ended September 30,~~ 2018 and ~~2017,~~2019 ~~the~~future ~~Company~~undiscounted ~~recorded~~cash ~~$262~~flows ~~and~~is ~~$280,~~mainly ~~respectively,~~due into ~~“Selling, general and administrative expenses” for restricted stock awards. For~~ the ~~nine~~acquisition ~~months~~of ~~ended~~Avista ~~September 30,~~on ~~2018~~January ~~and 2017~~2, ~~the~~2019. ~~Company~~See ~~recorded~~Note ~~$445~~4 ~~and $474, respectively, in “Selling, general and administrative expenses”~~ for ~~restricted~~additional ~~stock~~information ~~awards. As of September 30, 2018, total compensation cost related to unvested restricted stock not yet recognized was $88. The cost will be amortized~~ on athis ~~straight-line basis over the remaining weighted-average vesting period of 0~~acquisition.~~1 years.~~

~~The Company granted equity-settled performance shares~~ (~~“PS”~~12) toAccumulated ~~certain~~Other ~~executives. PS~~Comprehensive awards provide the recipient the right to receive a certain number of shares of the Company’s common stock in the future, which depends on the Company’s level of achievement of net revenue and EBITDA growth as compared to the net revenue and EBITDA growth of the members of a specified peer group of companies over a three year period. For the three months ended September 30, 2018 and 2017, the Company recorded a benefit of $353 and expense of $821, respectively, in “Selling, general and administrative expenses” related to these PS awards. For the nine months ended September 30, 2018 and 2017, the Company recorded expense of $479 and $2,534, respectively, in “Selling, general and administrative expenses” related to these PS awards. As of September 30, 2018, total compensation cost related to unvested performance shares not yet recognized was $2,768. The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of 0.9 years.Income/(Loss)

The following tables provide the changes in Accumulated other comprehensive income (13“AOCI”) ~~Retirement~~by ~~Plans~~component (pension, net of tax) for the three months ended March 31, 2019 and 2018:

The Company recognizes all components of net periodic benefit cost except service costs in “Other expenses, net” in its income statement. Service costs are recognized in “Selling, general and administrative expenses” and “Cost of goods sold” in its income statement depending on the functional area of the underlying employees included in the plan. As a result of the adoption of ASU 2017-07, the Company recorded $167 and $649 to “Other expenses, net” for the three and nine months ended September 30, 2018,

	Foreign Currency Translation Adjustments			Interest Rate Swap			Pension Plans			Total
Balance as of December 31, 2018	$	(27,736	)	$	-		$	(32,401	)	$	(60,137	)
Other comprehensive loss before reclassifications		(4,778	)		(2,002	)		-			(6,780	)
Amounts reclassified from accumulated other comprehensive loss		-			6			241			247
Net current-period other comprehensive (loss)/income		(4,778	)		(1,996	)		241			(6,533	)
Balance as of March 31, 2019	$	(32,514	)	$	(1,996	)	$	(32,160	)	$	(66,670	)


	Foreign Currency Translation Adjustments			Interest Rate Swap			Pension Plans			Total
Balance as of December 31, 2017	$	(12,040	)	$	-		$	(30,188	)	$	(42,228	)
Other comprehensive income before reclassifications		2,929			-			-			2,929
Amounts reclassified from accumulated other comprehensive loss		-			-			295			295
Net current-period other comprehensive income		2,929			-			295			3,224
Balance as of March 31, 2018	$	(9,111	)	$	-		$	(29,893	)	$	(39,004	)

2420

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

~~respectively,~~The ~~which~~following ~~formerly~~table ~~would~~provides ~~have~~the ~~been~~reclassifications ~~recorded~~from asAOCI ~~“Selling,~~by ~~general~~component ~~and administrative expenses” or “Cost of goods sold.” To conform to the current year presentation,~~ for the three ~~and nine~~ months ended ~~September 30,~~March ~~2017~~31, ~~the~~2019 ~~Company reclassified $384~~ and ~~$1,107, respectively, from “Selling, general and administrative expenses” and $54 and $161, respectively, from “Cost of goods sold” to “Other expenses, net.”~~2018:

Details about AOCI Components	Three Months Ended March 31, 2019			Three Months Ended March 31, 2018
Losses on cash flow hedge:
Interest rate swap	$	(6	)	$	-

Amortization of defined benefit pension items:
Actuarial losses		(323	)		(404	)
Prior service credit		-			1
Total before tax		(323	)		(403	)
Tax benefit		82			108
Net of tax		(241	)		(295	)
Total reclassification for the period	$	(247	)	$	(295	)

The Company recognizes all components of net periodic benefit cost except service costs in “Other expenses, net” in its income statement. Service costs are recognized in “Selling, general and administrative expenses” and “Cost of goods sold” in its income statement depending on the functional area of the underlying employees included in the plan. Interest rate swaps are recorded as “Interest expense, net” on the Company’s income statement.

(13)	Stock Based Compensation

The Company recognizes compensation costs for stock options awarded to employees based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average fair value per share for the stock options granted to employees during the three months ended March 31, 2019 was $15.04. No stock options were granted during the three months ended March 31, 2018.

For the three months ended March 31, 2019 and 2018, the Company recorded $1,062 and $1,039, respectively, in “Selling, general and administrative expenses” for stock options. As of March 31, 2019, the total compensation cost related to unvested stock options not yet recognized was $9,685. The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of 2.6 years.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

The following table is a summary of the Company’s stock options:

Options	Number of Shares			Weighted Average Exercise Price
Outstanding at December 31, 2018		1,051,623		$	41.41
Granted		65,000			39.66
Exercised		(4,000	)		16.25
Forfeited or expired		(6,150	)		46.02
Outstanding at March 31, 2019		1,106,473			41.37
Exercisable at March 31, 2019		452,860		$	34.39

The aggregate intrinsic values for all stock options exercised for the three months ended March 31, 2019 and 2018 were $89 and $3,274, respectively. The aggregate intrinsic values for all stock options outstanding and exercisable as of March 31, 2019 were $3,401 and $3,401, respectively.

The following table is a summary of the Company’s nonvested stock options, restricted stock and performance shares for which the requisite service period has not been rendered but that are expected to vest on the achievement of a performance condition:

	Nonvested
	Stock Options					Restricted Stock				Performance Shares
	Number of Shares			Weighted- Average Grant-Date Fair Value		Number of Shares		Weighted- Average Grant-Date Fair Value		Number of Shares			Weighted- Average Grant-Date Fair Value
Nonvested at December 31, 2018		601,513		$	17.83		-	$	-		152,000		$	46.61
Granted		65,000			15.04		25,000		44.21		5,000			45.64
Vested during period		(7,000	)		9.26		-		-		-			-
Forfeited		(5,900	)		17.36		-		-		(5,750	)		40.65
Nonvested at March 31, 2019		653,613		$	17.65		25,000	$	44.21		151,250		$	46.80

The Company granted restricted stock units during the three months ended March 31, 2019 to certain executives which will vest over a two year period. For the three months ended March 31, 2019 and 2018, the Company recorded $96 and $6, respectively, in “Selling, general and administrative expenses” for restricted stock units. As of March 31, 2019, total compensation cost related to nonvested restricted stock not yet recognized was $1,009. The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of 1.8 years.

The Company granted equity-settled performance shares (“PS”) to certain executives. PS awards provide the recipient the right to receive a certain number of shares of the Company’s common stock in the future, which depends on the Company’s level of achievement of net revenue and EBITDA growth as compared to the net revenue and EBITDA growth of the members of a specified peer group of companies over a three year period. For the three months ended March 31, 2019 and 2018, the Company recorded $501 and $605, respectively, in “Selling, general and administrative expenses” related to performance shares. As of March 31, 2019, total compensation cost related to nonvested performance shares not yet recognized was $3,815. The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of 1.5 years.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

(14)	Retirement Plans

Domestic Pension Plan

The components of net periodic benefit cost/(credit)~~/cost~~ for the Company’s domestic pension plan (which was frozen in 2007) for the three ~~and nine~~ months ended ~~September 30~~March 31, ~~2018~~2019 and ~~2017~~2018 were as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2018			2017			2018			2017
	2019			2018
Components of net periodic benefit (credit)/cost
Components of net periodic benefit cost/(credit)
Interest cost	$	~~511~~543		$	~~553~~510		$	~~1,532~~		$	~~1,661~~
Expected return on plan assets		(~~792~~682	)		(~~677~~792	)		~~(2,376~~	)		~~(2,031~~	)
Recognized actuarial loss		~~180~~207			~~199~~179			~~539~~			~~599~~
Net periodic benefit (credit)/cost	$	(101	)	$	75		$	(305	)	$	229
Net periodic benefit cost/(credit)	$	68		$	(103	)

International Pension Plan

The components of net periodic benefit cost for the Company’s international pension plan for the three ~~and nine~~ months ended ~~September 30~~March 31, ~~2018~~2019 and ~~2017~~2018 were as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2018			2017			2018			2017
	2019			2018
Components of net periodic benefit cost
Service cost	$	~~245~~278		$	~~247~~270		$	~~768~~		$	~~700~~
Interest cost		~~176~~167			~~192~~194			~~552~~			~~545~~
Recognized actuarial loss		93116			94103			~~292~~			~~268~~
Amortization of prior service credit		(1	)		(1	)		(3	)		(3	)
Amortization of prior service benefit		-			(1	)
Net periodic benefit cost	$	~~513~~561		$	~~532~~566		$	~~1,609~~		$	~~1,510~~

(1415) Segment Information

Cambrex is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies.

~~Including~~Due to the ~~Company’s~~acquisitions ~~acquisition~~ of Avista and Halo, ~~Pharma~~and onto ~~September~~be 12consistent with how the business is managed, ~~2018~~the Company now reports its results in three reportable segments, Drug Substance (“DS”), Drug Product (“DP”) and Early Stage Development and Testing (“ESDT”). The DS segment is comprised of the legacy Cambrex ~~has~~API ~~six~~business ~~manufacturing~~excluding ~~facilities~~the High Point facility, which was moved to the ESDT segment. The DP segment includes the former Halo business. The ESDT segment includes the former Avista business, in addition to the High Point facility.

2523

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

~~Operating~~DS ~~segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker~~ (~~the~~formerly Company’s Chief Executive Officer) in making decisions on how to allocate resources and assess performance. To be in alignment with the financial information received by the Chief Executive Officer and how the business is managed, the Company’s operating segments were aggregated to form two reportable segments, Active Pharmaceutical Ingredients (“APIs”) and Finished Dosage Form (“FDF”). While there are regulatory similarities between the two segments the products are different in that the API segment produces products that are sold to pharmaceutical companies that further process the Company’s product into a finished dosage form product that is then distributed directly to the patient. The FDF segment only manufactures and develops final dosage form products. All purchase accounting adjustments are recorded by the reporting segment.)

~~API’s:~~ The Company’s ~~API~~DS segment is comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products consist of APIs and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products.

~~FDF: The~~DP ~~Company’s~~(formerly FDF ~~segment consists of contract development and commercial manufacturing of finished dosage form products including oral solids, liquids and creams, and sterile and non-sterile ointments.~~)

The Company’s DP segment consists of contract development and commercial manufacturing of finished dosage form products including oral solids, liquids and creams, and sterile and non-sterile ointments.

ESDT

The Company’s ESDT segment provides a combination of analytical testing, early stage process chemistry, formulation development, manufacturing, and solid state chemistry services.

The Company’s Corporate headquarters provides management and administrative services to support the Company, and consists of certain aspects of the Company’s executive management, corporate relations, legal, compliance, human resources, information technology and finance departments. The Company allocates certain corporate expenses to each of its segments. Depreciation and amortization on certain assets are not allocated to the Company’s reportable segments.

The Company evaluates the performance of its segments based on segment operating profit. Transactions between reportable segments are not material. The Company does not allocate interest expense or income taxes to the operating segments. Discontinued operations are not recorded by the reportable segments. The Company accounts for total assets on a consolidated basis and does not allocate or disclose it for each reportable segment. The chief operating decision maker does not review segment’s assets.

The following table summarizes the Company’s financial information by reportable segment:

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2018			2017			2018			2017
	2019			2018
Gross sales by segment
Net revenue by segment
APIs	$	99,445		$	112,233		$	385,789		$	350,431
DS	$	112,060		$	136,607
FDF		4,786			-			4,786			-
DP		24,484			-
Total reported gross sales		104,231			112,233			390,575			350,431
ESDT		22,912			4,490
Operating profit/(loss) by segment
Total reported net revenue		159,456			141,097
APIs		16,872			31,932			101,436			106,779
Operating profit/(loss) by segment
FDF		114			-			114			-
DS		31,181			35,365
Total segment operating profit		16,986			31,932			101,550			106,779
DP		(250	)		-
Corporate operating loss		(10,354	)		(6,389	)		(19,885	)		(18,670	)
ESDT		(2,517	)		(399	)
Total reported operating profit	$	6,632		$	25,543		$	81,665		$	88,109
Total segment operating profit		28,414			34,966
Corporate operating loss		(8,090	)		(4,585	)
Total reported operating profit	$	20,324		$	30,381

2624

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

(1516) Contingencies

The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company continually assesses known facts and circumstances as they pertain to applicable legal and environmental matters and evaluates the need for reserves and disclosures as deemed necessary based on these facts and circumstances. These matters, either individually or in the aggregate, could result in actual costs that are significantly higher than the Company’s current assessment and could have a material adverse effect on the Company's operating results and cash flows in future reporting periods. Based upon past experience, the Company believes that payments significantly in excess of current reserves, if required, would be made over an extended number of years.

Environmental

In connection with laws and regulations pertaining to the protection of the environment, the Company and its subsidiaries are a party to several environmental proceedings and remediation activities and along with other companies, have been named a potentially responsible party (“PRP”) for certain waste disposal sites ("Superfund sites"). All of the liabilities currently recorded on the Company’s balance sheet for environmental proceedings are associated with discontinued operations. The Company had insurance policies in place at certain of the discontinued operations for certain years that the Company believes should cover some portion of the recorded liabilities or potential future liabilities and the Company expects the net cash impact related to the contingencies described below to be reduced by the applicable income tax rate.

It is the Company’s policy to record appropriate liabilities for environmental matters where remedial efforts are probable and the costs can be reasonably estimated. Such liabilities are based on the Company’s estimate of the undiscounted future costs required to complete the remedial work. Each of these matters is subject to various uncertainties, and it is possible that some of these matters will be decided against the Company. The resolution of such matters often spans several years and frequently involves regulatory oversight or adjudication. Additionally, many remediation requirements are fluid and are likely to be affected by future technological, site and regulatory developments. It is not possible at this time for the Company to determine fully the effect of all asserted and unasserted claims on its consolidated financial condition, results of operations or liquidity; however, to the extent possible, where asserted and unasserted claims can be estimated and where such claims are considered probable, the Company would record a liability. Consequently, the ultimate liability with respect to such matters, as well as the timing of cash disbursements, is uncertain.

In matters where the Company is able to reasonably estimate the probable and estimable costs associated with environmental proceedings, the Company accrues for the estimated costs associated with the study and remediation of applicable sites. At ~~September 30~~March 31, ~~2018~~2019, ~~these~~the reserves were $17,~~656~~292, of which $16,~~655~~505 is included in “Other non-current liabilities” on the Company’s balance sheet. At December 31, ~~2017~~2018, ~~the~~these reserves were $17,~~511~~411, of which $16,~~976~~599 is included in “Other non-current liabilities” on the Company’s balance sheet. The ~~increase~~decrease in the reserves includes ~~adjustments~~payments ~~to reserves~~ of $~~898,~~315 partially offset by ~~payments~~adjustments to reserves of $~~753~~196. The reserves are adjusted periodically as remediation efforts progress or as additional technical, regulatory or legal information becomes available. Given the uncertainties regarding the outcome of investigative and study activities, the status of laws, regulations, enforcement, policies, the impact of other PRPs, technology and information related to individual sites, the Company does not believe it is possible to currently develop an estimate of the range of reasonably possible environmental loss in excess of its reserves.

2725

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

Bayonne

As a result of the sale of a Bayonne, New Jersey facility, the Company became obligated to investigate site conditions and conduct required remediation under the New Jersey Industrial Site Recovery Act. The Company ~~completed~~is completing an investigation and sampling plan at the property pursuant to the New Jersey Department of Environmental Protection’s (“NJDEP”) private oversight program. The results ~~have~~will ~~been~~be used to develop a proposed remedial action work plan for the site. Among other things, the remedial plan ~~sets~~is anticipated to set forth further details of the proposed cleanup, including the removal and/or encapsulation of certain impacted soils and implementation of engineering controls and deed restrictions. As of ~~September 30~~March 31, ~~2018~~2019, the Company’s reserve was $~~635~~556.

Clifton and Carlstadt

The Company has implemented a sampling and pilot program in Clifton and Carlstadt, New Jersey pursuant to the NJDEP private oversight program. The results of the sampling and pilot program to date have been used to develop an estimate of the Company's future liability for remediation costs, and the Company continues to move forward with the projects at each site in accordance with the established schedules and work plans. As of ~~September 30~~March 31, ~~2018~~2019, the Company’s reserve was $1,~~842~~754.

Berry’s Creek

The Company received a notice from the United States Environmental Protection Agency (“USEPA”) that two subsidiaries of the Company are considered PRPs at the Berry’s Creek Study Area in New Jersey. These subsidiaries are among many other PRPs that were listed in the notice. Pursuant to the notice, the PRPs have been asked to perform a remedial investigation (“RI”) and feasibility study (“FS”) of the Berry’s Creek site. The Company has joined the group of PRPs and entered into an Administrative Settlement Agreement (“Agreement”) and Order on Consent with the USEPA agreeing to jointly conduct or fund an appropriate remedial investigation and feasibility study of the Berry’s Creek site with the other PRPs in the Agreement. The PRPs have engaged consultants to perform the work specified in the Agreement and develop a method to allocate related costs among the PRPs.

In June 2016, the PRPs received a request from USEPA to amend the RI/FS Work Plan to accommodate a phased, iterative approach to the Berry’s Creek remediation. USEPA requested an initial Phase I remedy that focuses on a portion of the site, namely, sediments in Upper and Middle Berry’s Creek and the marsh in Upper Peach Island Creek. Any subsequent remedial action will occur after the implementation and performance monitoring of this Phase I remedy and the extent of future action is expected to be at least partially determined by the outcome of this initial phase. In April 2017, USEPA approved the requested addendum to the RI/FS Work Plan, which included the description of the phased and adaptive management approach to the Berry’s Creek remedy.

In September 2018, USEPA issued its Record of Decision (“ROD”) for an interim remedy at Berry’s Creek. The interim remedy calls for, among other things, dredging and capping of contaminated sediments. The next step in the process is to design the remedy (“Remedial Design”). USEPA issued a letter to the Berry’s Creek PRP Group in September 2018 that provided notice of potential liability and a request that the PRP Group agree to perform the Remedial Design. USEPA provided a draft settlement agreement and statement of work to implement the Remedial Design. As a member of the Berry’s Creek PRP Group, the Company will participate in the PRP Group’s ~~response~~engagement towith USEPA on Remedial Design, and is coordinating with PRP Group members and PRP Group common counsel ~~on that response~~accordingly.

The estimated costs for the interim remedy may be further developed and the Company’s accrual may change based upon revisions to cost estimates. As of ~~September~~March 3031, ~~2018~~2019, the Company’s reserve was $9,~~688~~647. ~~At this time it is not known when the costs for the complete remediation plan will be estimable, and~~

2826

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

At this time it is not known when the costs for the complete remediation plan will be estimable, and as such, no accrual beyond the interim remedy has been recorded. The Company’s share has been preliminarily estimated by the PRP group at 2.4%. While the Company will defend its position that its share should be reduced from the current level, its share could be increased or decreased depending on the outcome of the final allocation process that will take place in future periods.

While any resolution of this matter is not expected to materially impact the Company’s operations or financial position, it could be material to the financial statements in the period recorded.

In July 2014, the Company received a notice from the U.S. Department of the Interior, U.S. Fish & Wildlife Service, regarding the Company’s potential liability for natural resource damages at the Berry’s Creek site and inviting the Company to participate in a cooperative assessment of natural resource damages. Most members of the Berry’s Creek PRP group received such notice letters, and the PRP Group coordinated a joint response, which was to decline participation in a cooperative assessment at this time, given existing investigation work at the site. The cost of any future assessment and the ultimate scope of natural resource damage liability are not yet known.

Maybrook Site

A subsidiary of Cambrex is named a PRP of a site in Hamptonburgh, New York by the USEPA in connection with the discharge, under appropriate permits, of wastewater at that site prior to Cambrex's acquisition in 1986. The PRPs implemented soil remediation which was completed in 2012 pending approval by the USEPA. The PRPs will continue implementing the ground water remediation at the site. USEPA completed its 5-year review report in August 2018, and USEPA’s review of the site remedy is on-going. It is unclear if such review, together with an agreed proposed modification to the USEPA Consent Decree, will result in any additional site work. In November 2018, under a statewide initiative, the New York State Department of Environmental Conservation (“NYSDEC”) requested that the PRPs perform additional sampling for certain “emerging contaminants.” NYSDEC approved the PRPs work plan in December 2018, and the sampling is anticipated to be performed during the second quarter of 2019. As of ~~September 30~~March 31, ~~2018~~2019, the Company’s reserve was $~~329~~365, to cover long-term ground water monitoring and related costs.

Harriman Site

Subsidiaries of Cambrex and Pfizer are named as responsible parties for the Company’s former Harriman, New York production facility by the New York State Department of Environmental Conservation (“NYSDEC”). A final Record of Decision (“ROD”) describing the Harriman site remediation responsibilities for Pfizer and the Company was issued in 1997 (the “1997 ROD”) and incorporated into a federal court Consent Decree in 1998 (the “Consent Decree”). In December 2013, the Company, Pfizer and the NYSDEC entered into a federal court stipulation, which the court subsequently endorsed as a court order, resolving certain disputes with the NYSDEC about the scope of the obligations under the Consent Decree and the 1997 ROD, and requiring the Company and Pfizer to carry out an environmental investigation and study of certain areas of the Harriman Site.

Site clean-up work under the 1997 ROD, the Consent Decree and the 2013 stipulation is ongoing and is being jointly performed by Pfizer and the Company, with NYSDEC oversight. Since 2014, Pfizer and the Company have performed supplemental remedial investigation measures requested by the NYSDEC, and the findings have been submitted to NYSDEC in various reports, including a study evaluating the feasibility of certain remedial alternatives in August 2016. By letter dated January 5, 2017, NYSDEC disapproved such feasibility study report and requested certain revisions to the report. The Company and Pfizer engaged in further discussions with NYSDEC and have agreed to submit a revised version of the August 2016 feasibility study to address certain of NYSDEC’s requests. In September 2017, the NYSDEC requested that Pfizer, the Company and the current owner of the Harriman Site, ELT Harriman LLC (“ELT”), conduct an investigation of additional constituents not addressed under the 1997 ROD based on the detection of those constituents at the Harriman Site and other properties in the area. The parties have requested more information from the State of New York to evaluate the request, while also responding to NYSDEC that no further investigation was warranted.27

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

As it is too soon to determine whether the NYSDEC’s requests or the reports and remedial plans, when finalized, will result in any significant changes to the Company’s responsibilities, no change to the reserve has been made. ELT is conducting other investigation and remediation activities under a separate NYSDEC directive.

No final remedy for the site has been determined, which will follow further discussions with the NYSDEC. The Company estimates the range for its share of the liability at the site to be between $2,000 and $7,000. As of ~~September 30~~March 31, ~~2018~~2019, the Company’s reserve was $3,365. At this time, the Company is unable to provide an estimate of the ultimate investigative and remedial costs to the Company for any final remedy selected by the NYSDEC.

The Company intends to enforce all of its contractual rights to recover costs and for indemnification under a 2007 settlement agreement, and has filed such claims in an arbitration proceeding against ELT and the immediately preceding owner, Vertellus Specialties Holdings (“Vertellus”). ELT has filed counterclaims, and has threatened to file additional counterclaims, for contractual indemnification and for breach of the settlement agreement against the Company. Currently, the arbitration proceeding is stayed indefinitely. In May 2016, some but not all of the Vertellus entities who are parties to the Company’s 2007 settlement agreement filed for restructuring under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company has filed several claims as creditors in the bankruptcy proceeding and will continue to monitor the bankruptcy proceeding.

Scientific Chemical Processing (“SCP”) Superfund Site

A subsidiary of Cambrex was named a PRP of the SCP Superfund site, located in Carlstadt, New Jersey, along with approximately 130 other PRPs. The site is a former waste processing facility that accepted various waste for recovery and disposal including processing wastewater from this subsidiary. The PRPs are in the process of implementing a final remedy at the site. The SCP Superfund site has also been identified as a PRP in the Berry’s Creek Superfund site (see previous discussion). While the Company continues to dispute the methodology used by the PRP group to arrive at its interim allocation for cash contributions, the Company has paid the funding requests. A final allocation of SCP Site costs (excluding Berry’s Creek costs) is expected to be finalized in ~~2018~~2019. As of ~~September 30~~March 31, ~~2018~~2019, the Company’s reserve was $732, of which approximately $468 is expected to be covered by insurance.

~~Newark Bay Complex~~28

The USEPA and a private party group are evaluating remediation plans for the Passaic River, Newark Bay, Hackensack River, Arthur Kill, Kill Van Kull and adjacent waters (the “Newark Bay Complex”). Although the Company is not involved in the USEPA action, it continues to monitor developments related to the site due to its past involvement in a previously settled state action relating to the Newark Bay Complex. The USEPA has finalized its decision on a cleanup plan for 8.3 miles of the lower Passaic River, and has estimated the cost of this plan at $1.38 billion. Due to the uncertainty of the future scope and timing of any possible claims against the Company, no liability has been recorded.

The Company is involved in other related and unrelated environmental matters where the range of liability is not reasonably estimable at this time and it is not foreseeable when information will become available to provide a basis for adjusting or recording a reserve, should a reserve ultimately be required.

CAMBREX CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except share data)

(Unaudited)

~~Litigation~~Newark ~~and~~Bay ~~Other Matters~~Complex

~~Lorazepam~~The USEPA and ~~Clorazepate~~a private party group are evaluating remediation plans for the Passaic River, Newark Bay, Hackensack River, Arthur Kill, Kill Van Kull and adjacent waters (the “Newark Bay Complex”). Although the Company is not involved in the USEPA action, it continues to monitor developments related to the site due to its past involvement in a previously settled state action relating to the Newark Bay Complex. The USEPA has finalized its decision on a cleanup plan for 8.3 miles of the lower Passaic River, and has estimated the cost of this plan at $1.38 billion. Due to the uncertainty of the future scope and timing of any possible claims against the Company, no liability has been recorded.

InThe ~~1998, the~~ Company ~~and~~is ainvolved ~~subsidiary~~in ~~were~~other ~~named~~related ~~as defendants along with Mylan Laboratories, Inc. (“Mylan”)~~ and ~~Gyma~~unrelated ~~Laboratories,~~environmental ~~Inc.~~matters ~~(“Gyma”)~~where ~~in a proceeding instituted by~~ the ~~Federal~~range ~~Trade Commission in the United States District Court for the District~~ of ~~Columbia~~liability ~~(the~~is ~~“District~~not ~~Court”).~~reasonably ~~Suits~~estimable ~~were~~at ~~also~~this ~~commenced~~time ~~by several State Attorneys General~~ and ~~class~~it ~~action~~is ~~complaints~~not byforeseeable ~~private~~when ~~plaintiffs~~information inwill ~~various~~become ~~state~~available ~~courts.~~to ~~The~~provide ~~suits~~a ~~alleged~~basis ~~violations~~for ofadjusting ~~the~~or ~~Federal~~recording ~~Trade~~a ~~Commission~~reserve, ~~Act~~should ~~arising~~a ~~from~~reserve ~~exclusive~~ultimately ~~license~~be ~~agreements between the Company and Mylan covering two APIs (Lorazepam and Clorazepate)~~required.

In(17) ~~2003,~~Discontinued Cambrex paid $12,415 to Mylan in exchange for a release and full indemnity against future costs or liabilities in related litigation brought by the purchasers of Lorazepam and Clorazepate, as well as potential future claims related to the ongoing matter.Operations

Following trial in 2008 in the sole remaining case brought by four health care insurers, the District Court entered judgment against Mylan, Gyma and Cambrex. The judgment was appealed to the United States Court of Appeals for the District of Columbia Circuit (the “D.C. Circuit”) in 2011, resulting in a remand to the District Court. On remand, the District Court dismissed certain self-funded customer plaintiffs due to their failure to satisfy the requirements of federal jurisdiction. Subsequently, the District Court entered an order remitting certain damages. Without fees, costs, or post-judgment interest, the current judgment against Mylan, Gyma, and Cambrex was $67,260. Mylan, Gyma, and Cambrex again appealed to the D.C. Circuit. In July 2018, Mylan, Gyma, and Cambrex reached a settlement with the remaining plaintiffs. After the settlement was finalized, the D.C. Circuit issued an order dismissing the appeal. Cambrex has been fully indemnified by Mylan for the settlement payments.

(16) Discontinued Operations

For all periods presented, financial results for discontinued operations relate to environmental investigation and remediation expenses for divested sites. The following table is a reconciliation of the pre-tax loss on discontinued operations to the net loss on discontinued operations, as presented on the income statement:

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2018			2017			2018			2017
	2019			2018
(Loss)/income from discontinued operations, pre-tax	$	(99	)	$	126		$	(855	)	$	(1,946	)
Loss from discontinued operations, pre-tax	$	(152	)	$	(237	)
Income tax benefit/(expense)		13			(106	)		145			622
Income tax benefit		34			46
(Loss)/income from discontinued operations, net of tax	$	(86	)	$	20		$	(710	)	$	(1,324	)
Loss from discontinued operations, net of tax	$	(118	)	$	(191	)

As of ~~September 30~~March 31, ~~2018~~2019 and December 31, ~~2017~~2018, liabilities recorded on the Company’s balance sheet related to discontinued operations were $17,~~656~~292 and $17,~~511~~411, respectively. At this time, the Company cannot reasonably estimate the period of time during which the involvement is expected to continue. Net cash used in discontinued operations for the ~~nine~~three months ended ~~September 30~~March 31, ~~2018~~2019 and ~~2017~~2018 were $~~557~~217 and $1292,~~185,~~ respectively. Refer to Note 1516 to the Company’s consolidated financial statements for further disclosures on the Company’s environmental contingencies.

3129

CAMBREX CORPORATION AND SUBSIDIARIES

(in thousands, except share data)

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Executive Overview

~~The~~In ~~following~~January ~~summarizes~~2019, the Company’s ~~performance~~purchased ~~for~~Avista Pharma Solutions (“Avista”), an early clinical phase contract development, manufacturing and testing organization. In September 2018, the ~~third~~Company ~~quarter~~completed the acquisition of ~~2018:~~Halo Pharma (“Halo”) for approximately $425,000. As a result, and consistent with how the business is managed, the Company has three reportable segments, Drug Substance (“DS”), Drug Product (“DP”) and Early Stage Development & Testing (“ESDT”).

• The ~~Company~~following ~~acquired~~summarizes ~~100%~~the ofCompany’s ~~Halo~~performance ~~Pharma~~for onthe ~~September~~first ~~12,~~quarter ~~2018~~of ~~for $425,000.~~2019:

• The Company ~~adopted~~acquired ~~ASC~~Avista ~~606 - Revenue from Contracts with Customers~~ on January 12, ~~2018~~2019 ~~using~~for ~~the~~approximately ~~modified retrospective method. The cumulative effect adjustment recorded to retained earnings as of January 1, 2018 was~~ $16252,~~219, net of tax~~000.

• Net revenue ~~decreased~~increased 713.10% on a reported basis compared to the ~~third~~first quarter of ~~2017~~2018. Net revenue, excluding currency impact, ~~decreased~~increased 516.65%. ~~Excluding the impact of the new revenue recognition standard, net revenue decreased 8.8% on a reported basis.~~

• Gross margins decreased to 3134.34% from 4136.70% in the ~~third~~first quarter of ~~2017~~2018. ~~Excluding the impact of the new revenue recognition standard, gross margins were 38.3%.~~

• Net debt was $~~227~~429,~~865~~961 compared to ~~net cash of~~ $~~171~~204,~~348~~148 at ~~June~~December 3031, 2018. The change is primarily the result of acquiring ~~Halo~~Avista, ~~Pharma~~partially offset by positive cash flows from operations.

Critical Accounting Estimates

The Company’s critical accounting estimates are those that require the most subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company bases its estimates on historical experience and on other assumptions that are deemed reasonable by management under each applicable circumstance. Actual results or amounts could differ from estimates and the differences could have a material impact on the consolidated financial statements. See the “Critical Accounting Estimates” section of the Company’s Annual Report on Form 10-K for the period ended December 31, 2017 for further discussion of the Company’s critical accounting policies, the underlying judgments and uncertainties affecting their application and the likelihood that materially different amounts would be reported under different conditions or using different assumptions. The policy updates from the previously filed Form 10-K are as follows:

Revenue Recognition

2018 results are accounted for under the following new policy:

The Company adopted Topic 606 Revenue from Contracts with Customers on January 1, 2018 using the modified retrospective method. As a result, the Company has changed its accounting policy for revenue recognition as detailed below. The cumulative effect of initially applying the new revenue standard was recorded as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under accounting standard Topic 605 which was in effect for those periods.

Shipping and handling costs are treated as fulfillment costs and estimates for the portion of revenue recognized on performance obligations recognized over time are accrued.

For variable consideration arrangements where the transaction price fluctuates based on quantity, the most likely estimated quantity is assumed using forecasts provided by the customer.

Single-use products

Multi-use products

Service revenue

Contract balances

The timing of revenue recognition, billings and cash collections results in billed trade receivables, contracts assets (unbilled receivables), and contract liabilities (customer advances and deferred revenue). For each reporting period presented, the Company reports contract balances in a net contract asset or liability position on a contract-by-contract basis. Contract assets are recorded when the right to consideration is conditioned on something other than the passage of time. When an entity’s right to consideration is unconditional, the receivable is recorded within Trade Receivables on the balance sheet. Contract liabilities represent advance payments from customers, and deferred revenue. Contract assets will convert to trade receivables or cash and current contract liabilities will convert into revenue within a one-year period.

All prior periods presented are accounted for under the following policy:

Revenues are generally recognized when title to products and risk of loss are transferred to customers. Additional conditions for recognition of revenue are that collection of sales proceeds is reasonably assured and the Company has no further performance obligations.

Amounts billed in advance are recorded as contract liabilities on the balance sheet. Since payments received are sometimes non-refundable, the termination of a contract by a customer prior to its completion could result in an immediate recognition of deferred revenue relating to payments already received but not previously recognized as revenue.

The Company bills a portion of freight cost incurred on shipments to customers. Amounts billed to customers are recorded within net revenues. Freight costs are reflected in cost of goods sold.

Income Taxes

Assumptions and Approach Used in Assessing the Need for a Valuation Allowance

This assessment, which is completed on a taxing jurisdiction basis, takes into account a number of types of evidence, including the following:

Results of Operations

Comparison of ~~Third~~First Quarter ~~2018~~2019 versus ~~Third~~First Quarter ~~2017~~2018

Net revenue in the ~~third~~first quarter of ~~2018~~2019 of $~~104~~159,~~618~~456 was $818,~~001~~359 or 713.10% ~~lower~~higher than the ~~third~~first quarter of ~~2017~~2018. Excluding a 13.5% unfavorable impact of foreign exchange compared to the ~~third~~first quarter of ~~2017~~2018, net revenue ~~decreased~~increased 516.65% primarily due to ~~lower volumes (5.7%). The decrease in volumes was driven by~~ the ~~Active~~acquisitions ~~Pharmaceutical~~of ~~Ingredients~~Halo ~~(“APIs”)~~and ~~segment~~Avista, partially offset by ~~Halo~~lower ~~revenues,~~volumes ~~which~~within ~~makes up~~ the ~~Finished~~DS ~~Dosage Form (“FDF”)~~ segment.

~~Excluding~~The ~~the~~following ~~impact~~table ofreflects ~~the new revenue recognition standard,~~ net revenue inby ~~the~~geographic ~~third~~area ~~quarter~~for ~~of 2018 decreased 8.8% compared to~~ the ~~third~~first ~~quarter~~quarters of ~~2017~~2019 toand ~~$102,704.~~ 2018:

The following table reflects net revenue by geographic area for the third quarters of 2018 and 2017:

	First quarter
	2019		2018
Europe	$	61,335	$	86,739
North America		86,693		47,673
Asia		6,057		4,670
Other		5,371		2,015
Total net revenue	$	159,456	$	141,097

	Third quarter
	2018		2017
Europe	$	62,146	$	62,395
North America		35,903		44,933
Asia		3,394		2,809
Other		3,175		2,482
Total net revenue	$	104,618	$	112,619

Gross margins in the first quarter of 2019 decreased to 34.4% from 36.0% in the first quarter of 2018. Gross profit in the first quarter of 2019 was $54,883 compared to $50,855 in the same period last year. Margins increased in the DS segment as discussed below.

~~Gross~~Drug ~~margins~~Substance in the third quarter of 2018 decreased to 31.3% from 41.7% in the third quarter of 2017. Gross profit in the third quarter of 2018 was $32,725 compared to $46,943 in the same period last year. Excluding the impact of the new revenue recognition standard, gross margins in the third quarter of 2018 decreased to 38.3%. Margins decreased in the APIs segment as discussed below.

Net revenue in the first quarter of 2019 of $112,060 was $24,547 or 18.0% lower than the first quarter of 2018. Excluding a 3.7% unfavorable impact of foreign exchange compared to the first quarter of 2018, net revenue decreased 14.3% primarily due to lower volumes of certain branded APIs, primarily our largest product, partially offset by higher sales of clinical phase products and generic APIs. Controlled substances were flat compared to the first quarter of 2018.

Net revenue in the third quarter of 2018 of $99,464 was $13,348 or 11.8% lower than the third quarter of 2017. Excluding a 1.7% unfavorable impact of foreign exchange compared to the third quarter of 2017, net revenue decreased 10.1% primarily due to lower volumes (10.2%). The decrease in volumes was driven by a decrease in all product categories. 30

~~Excluding~~Gross margins in the ~~impact~~first quarter of ~~the~~2019 ~~new~~increased ~~revenue~~to ~~recognition~~38.7% ~~standard,~~from ~~net~~36.6% ~~revenue~~ in the ~~third~~first quarter of 2018 ~~decreased 14~~.5% Gross ~~compared~~profit toin the ~~third~~first quarter of ~~2017~~2019 was $43,364 compared to $9649,~~408~~959 in the same period last year. The increase in margins was primarily driven by a favorable impact from foreign currency, favorable product mix related to generic APIs and lower inventory charges due to batch failures in 2018 partially offset by lower production volumes.

~~Gross~~Selling, ~~margins~~general and administrative (“SG&A”) expenses of $9,415 in the ~~third~~first quarter of ~~2018~~2019 decreased compared to ~~31.2%~~$11,534 ~~from 41.8%~~ in the ~~third~~first quarter of ~~2017~~2018. ~~Gross~~The ~~profit~~decrease inwas ~~the~~mainly ~~third~~due ~~quarter~~to oflower ~~2018~~consulting ~~was~~costs ~~$31,073~~associated ~~compared~~with toa ~~$47,135~~2018 inoperational ~~the~~excellence ~~same~~initiative ~~period~~(approximately ~~last~~$1,100) ~~year. Excluding~~and the impact of ~~the~~foreign ~~new~~currency ~~revenue~~(approximately ~~recognition~~$600). ~~standard~~SG&A, ~~gross~~as ~~margins~~a inpercentage ~~the~~of ~~third~~DS ~~quarter~~net ofrevenue, ~~2018~~was ~~were 38~~8.94%~~. The~~ ~~decrease~~ in ~~margins~~the ~~was~~first ~~primarily~~quarters ~~driven~~of by2019 ~~lower production volumes~~ and ~~higher raw material costs~~2018.

~~Selling,~~Research ~~general~~ and ~~administrative~~development (“SGR&AD”) expenses of $102,~~742~~768 inwere ~~the~~2.5% ~~third quarter~~ of ~~2018~~DS ~~decreased~~net ~~compared~~revenue ~~to $12,160~~ in the ~~third~~first quarter of ~~2017. The~~2019, ~~decrease~~compared ~~was mainly due~~ to an$3,060 ~~accounts~~or ~~receivable~~2.2% ~~write-off~~ in the ~~third~~first quarter of ~~2017~~2018. The ~~(approximately~~decrease ~~$700),~~was ~~lower~~primarily ~~consulting~~driven ~~costs~~by ~~associated with an operational excellence initiative (approximately $400) and~~ the impact of foreign currency ~~(approximately $300)~~. ~~Sales and marketing expenses were flat compared to the third quarter of 2017. SG&A, as a percentage of net revenue, was 10.8% in the third quarters of 2018 and 2017.~~

~~Research~~Operating ~~and~~profit ~~development (“R&D”) expenses of $3,459 were 3.5% of net revenue~~ in the ~~third~~first quarter of ~~2018~~2019 was $31,181 compared to $335,~~043~~365 ~~or 2.7% of net revenue~~ in the ~~third~~first quarter of ~~2017~~2018. The ~~increase~~decrease in operating profit was ~~primarily~~due ~~driven~~to lower gross profit partially offset by ~~higher~~lower ~~personnel~~operating ~~costs~~expenses as described above.

35Drug Product

~~Operating~~Halo ~~profit~~was purchased in ~~the~~September ~~third quarter of~~ 2018 ~~was~~and ~~$16,872~~comprises ~~compared~~all toof ~~$31,932 in~~ the ~~third~~DP ~~quarter of 2017~~segment. ~~The decrease in operating profit was due to lower gross profit partially offset by lower operating expenses as described above.~~

~~Excluding~~Net ~~the impact of the new~~ revenue ~~recognition standard, operating profit~~ in the ~~third~~first quarter of ~~2018~~2019 was $2324,~~319~~484.

~~FDF~~Gross margins in the first quarter of 2019 were 24.5%. Gross profit in the first quarter of 2019 was $5,997.

~~Net~~SG&A ~~revenue~~expenses were $6,168 in the ~~third~~first quarter of ~~2018~~2019 ~~was~~which ~~$5,154~~includes ~~for~~amortization ~~the~~of ~~period~~purchased ~~from~~intangibles ~~acquisition~~of ~~date~~$2,996. ~~September 12~~SG&A, ~~2018~~as ~~through~~a ~~September~~percentage ~~30, 2018. Excluding the impact~~ of ~~the~~DP ~~new~~net revenue, ~~recognition~~was ~~standard,~~25.2%. ~~net~~R&D ~~revenue~~expenses ~~was~~were ~~$6,296~~negligible.

~~Gross~~DP ~~margins~~had inan ~~the~~operating ~~third~~loss ~~quarter of 2018 were 32.1%. Gross profit~~ in the ~~third~~first quarter of ~~2018~~2019 ~~was $1,652. Excluding the impact~~ of ~~the new revenue recognition standard, gross margins in the third quarter of 2018 were 28.0% and gross profit would have been~~ $~~1,766~~250.

~~SG&A~~Early ~~expenses~~Stage ~~were~~Development ~~$1,141 in the third quarter of 2018. SG~~&A, ~~as a percentage of net revenue, was 22.1%.~~ Testing

~~FDF~~The ~~operating~~ESDT ~~profit~~segment ~~for~~consists ~~the~~of ~~period September 12~~Avista, ~~2018~~which ~~through September 30, 2018~~ was ~~$508. Excluding~~purchased ~~the~~on ~~impact~~January ~~of the new revenue recognition standard~~2, ~~operating~~2019 ~~profit~~and ~~would~~Cambrex’s ~~have~~High ~~been~~Point ~~$622~~facility. ~~Both exclude integration costs of $394.~~

~~The~~Net ~~Company’s~~revenue Corporate headquarters provides management and administrative services to support the Company, and consists of certain aspects of the Company’s executive management, corporate relations, legal, compliance, human resources, and information technology and finance departments. The Company allocates certain corporate expenses to each of its segments. SG&A expenses of $2,631 in the ~~third~~first quarter of ~~2018~~2019 ~~decreased compared to $5,007 in the third quarter of 2017. The decrease~~ was ~~mainly due to lower personnel related costs (approximately~~ $222,~~300).~~912 ~~R&D expenses of $729 in the third quarter of 2018 decreased~~ compared to $14,~~190~~490 in the ~~same~~first quarter ~~last~~of ~~year~~2018. The ~~decrease~~increase is ~~due~~primarily attributable to the ~~timing~~acquisition of ~~spending on the development of generic drug products~~Avista.

~~During~~Gross ~~the~~margins ~~third~~in ~~quarter of 2018,~~ the ~~Company~~first ~~completed~~quarter ~~the acquisition~~ of ~~100%~~2019 ofwere ~~Halo, a finished dosage form Contract Development and Manufacturing Organization~~24.1% ~~The~~compared ~~deal~~to ~~was structured as a stock purchase~~20.0% ~~The Company acquired two GMP compliant facilities, one~~ in ~~Whippany, NJ, USA,~~ the ~~other~~first inquarter ~~Mirabel,~~of ~~Quebec, Canada~~2018. ~~All~~Gross ~~acquisition~~profit ~~and~~in ~~integration costs have been expensed and totaled $7,388 for~~ the ~~three~~first ~~months~~quarter ~~ended September 30, 2018,~~ of ~~which~~2019 ~~$394~~ was ~~recorded~~$5,522 bycompared ~~the FDF segment. These costs have been recorded~~ to ~~“Acquisition~~$896 ~~and~~in ~~integration expenses” on~~ the ~~Company’s~~same ~~income~~period ~~statement.~~last year.

~~During~~SG&A ~~the~~expenses ~~second~~were ~~quarter of 2018~~$6,517 ~~the Company acquired a 19.9% equity investment~~ in ~~a European company (“Investee”). The Investee completed an initial public offering on a foreign exchange late in~~ the first quarter, ~~which reduced the Company’s ownership share to 16.3%. The Company’s investment is subject to a one-year prohibition on selling the shares. The Company has one seat on the Board~~ of ~~Directors~~2019 ofwhich ~~the~~includes ~~investee~~amortization and concluded it is able to exercise significant influence and that equity accounting would be appropriate. In accordance with ASC 825, the Company has elected to record this investment at fair value. The Company selected an appropriate valuation methodology to compute a discount for the lack of ~~marketability~~purchased tointangibles ~~be applied to the closing market price~~ of ~~the shares as of September 30~~$1, ~~2018~~390. ~~The fair value of the Company’s shares increased by $5~~SG&A,~~611~~ ~~at September 30, 2018 resulting in an unrealized gain that was recorded~~ as ~~“Unrealized~~a ~~gain~~percentage ~~on investment in equity securities” on the Company’s income statement. Since the shares owned by the Company are substantially in excess~~ of ~~the~~ESDT ~~daily~~net ~~trade volumes of the stock~~revenue, itwas ~~could~~28.4%. beR&D ~~difficult~~expenses towere ~~sell~~$316 ~~the shares~~ in ~~a timely manner when~~ the ~~restrictions~~first ~~lapse~~quarter ~~and it is possible the ultimate value to be realized by the Company could be significantly less upon a sale~~ of ~~the securities~~2019.

36ESDT had an operating loss in the first quarter of 2019 of $2,517 which includes integration expenses of $1,206. Operating loss for the first quarter of 2018 was $399.

Net interest expense was $725 in the third quarter of 2018 compared to $337 in the third quarter of 2017. The increase is due to interest expense on borrowings during the quarter to fund the Halo acquisition partially offset by higher interest income generated from higher cash balances. There was $325,000 outstanding on the Credit Facility at September 30, 2018. The average interest rate on debt was 3.6% in the third quarter of 2018. The Company did not have any debt outstanding as of September 30, 2017. 31

Income tax expense from continuing operations for the three months ended September 30, 2018 and 2017 was a benefit of $15,406 compared to an expense of $7,498, and an effective tax rate of 30.3%, respectively. Excluding the impacts of immediately recognizing certain effects of share-based compensation, acquisition and integration expenses, unrealized gain on investment in equity securities, a $2,105 benefit for finalizing the TCJA toll charge, and a $12,189 benefit for release of a state valuation allowance and the revaluation of state deferred tax balances due to New Jersey tax reform enacted during the quarter ended September 30, 2018, the effective tax rate would have been 19.6% for the three months ended September 30, 2018, compared to 33.2% for the three months ended September 30, 2017.Corporate

~~Income~~The ~~from~~Company’s ~~continuing~~Corporate ~~operations~~headquarters inprovides management and administrative services to support the ~~third~~Company, ~~quarter~~and consists of ~~2018~~certain ~~was~~aspects ~~$26~~of the Company’s executive management,~~815~~ corporate relations, orlegal, $0compliance, human resources, and information technology and finance departments.79 ~~per~~The ~~diluted~~Company ~~share,~~allocates ~~versus~~certain corporate expenses to each of its segments. SG&A expenses of $172,~~276~~941 orin the first quarter of 2019 decreased compared to $04,026 in the first quarter of 2018.52 The ~~per~~decrease ~~diluted~~was ~~share~~primarily due to lower due diligence costs and personnel related expenses. R&D expenses of $312 in the first quarter of 2019 decreased compared to $559 in the same ~~period~~quarter alast year. ~~ago~~The decrease is due to the timing of spending on the development of generic drug products.

~~Excluding~~All ~~the~~acquisition ~~impact~~and ofintegration costs related to the ~~new~~Halo ~~revenue~~and ~~recognition~~Avista ~~standard,~~acquisitions ~~income~~have ~~from~~been ~~continuing~~expensed ~~operations~~and intotaled ~~the~~$6,056 ~~third~~for ~~quarter~~the ofthree ~~2018~~months ~~was~~ended $March 31,~~818~~ or2019, of which $01,206 is reflected in the ESDT segment.94 ~~per~~These ~~diluted~~costs ~~share~~have been recorded to “Acquisition and integration expenses” on the Company’s income statement.

~~Comparison~~The Company recorded an unrealized loss of ~~First~~$569 ~~Nine~~related ~~Months~~to its investment in a European company. The loss was recorded as “Unrealized loss on investment in equity securities” on the Company’s income statement. Since the shares owned by the Company are substantially in excess of ~~2018~~the ~~versus~~daily ~~First~~trade ~~Nine~~volumes ~~Months~~of the stock, it could be difficult to sell the shares in a timely manner when the restrictions lapse in the second quarter of ~~2017~~2019 and it is possible the ultimate value to be realized by the Company could be significantly less upon a sale of the securities. The fair value of the Company’s share of the company was $12,055 at March 31, 2019. The Company has owned 16.3% of the European company since the second quarter of 2018.

Net ~~revenue~~interest expense was $5,624 in the first ~~nine~~quarter ~~months~~ of ~~2018~~2019 ofcompared ~~$397,761~~to ~~was~~ $~~45,582~~82 orin ~~12.9% higher than~~ the first ~~nine~~quarter ~~months~~ of ~~2017~~2018. ~~Excluding~~The aincrease ~~1.8%~~is ~~favorable~~due ~~impact~~to ofinterest ~~foreign~~expense ~~exchange~~on ~~compared~~borrowings to fund the ~~first~~Halo ~~nine~~and ~~months~~Avista ofacquisitions. ~~2017,~~There ~~net~~was ~~revenue~~$497,500 ~~increased~~outstanding ~~11.1%~~on asthe aCredit ~~result~~Facility ofat ~~higher~~March ~~volumes~~31, ~~(11~~2019.~~3%)~~ ~~partially~~The ~~offset~~average byinterest ~~lower~~rate ~~pricing~~on (0debt was 4.23%). ~~The~~in ~~increase~~the infirst ~~volumes~~quarter ~~was~~of ~~driven~~2019. byThe ~~the~~Company ~~APIs~~did ~~segment~~not ~~and~~have ~~the~~any ~~addition~~debt outstanding as of ~~the~~March ~~FDF~~31, ~~segment~~2018.

~~Excluding~~Income ~~the~~tax ~~impact~~expense offrom continuing operations for the ~~new~~three ~~revenue~~months ~~recognition~~ended ~~standard~~March 31, ~~net~~2019 ~~revenue~~and in2018 ~~the~~was ~~first~~$3,532 ~~nine~~and $5,786, respectively. The effective tax rate for the three months ofended March 31, 2019 and 2018 ~~decreased~~was 25.1% and 19.3%, respectively.6 Income tax expense for the three months ended March 31, 2018 would have been 19.8% excluding the impact of immediate recognition of certain effects of share-based compensation. The increase in the tax rate for 2019 as compared to 2018 is primarily due to state tax reform and the ~~first~~Company’s ~~nine~~expanded ~~months~~state ofpresence ~~2017~~due to ~~$339~~the Halo and Avista acquisitions,~~579.~~ and the geographic mix of income.

~~The~~Income ~~following~~from ~~table~~continuing ~~reflects~~operations ~~net~~in ~~revenue~~the byfirst ~~geographic~~quarter ~~area~~of ~~for~~2019 ~~the~~was ~~first~~$10,527, ~~nine~~or ~~months~~$0.31 ofper ~~2018~~diluted ~~and~~share, ~~2017:~~versus $24,249, or $0.72 per diluted share, in the same period a year ago.

	First nine months
	2018		2017
Europe	$	247,105	$	199,759
North America		127,341		131,995
Asia		11,246		12,875
Other		12,069		7,550
Total net revenue	$	397,761	$	352,179

Gross margins in the first nine months of 2018 decreased to 37.3% from 43.0% in the first nine months of 2017. Margins decreased in the APIs segment. Gross profit in the first nine months of 2018 was $148,372 compared to $151,377 in the same period last year.

Excluding the impact of the new revenue recognition standard, gross margins in the first nine months of 2018 decreased to 36.3%. Gross profit in the first nine months of 2018 would have been $123,384.

APIs

Net revenue in the first nine months of 2018 of $392,687 was $40,293 or 11.4% higher than the first nine months of 2017. Excluding a 1.8% favorable impact of foreign exchange compared to the first nine months of 2017, net revenue increased 9.6% as a result of higher volumes (9.8%) partially offset by lower pricing (0.2%). The increase in volumes was driven by higher sales of branded APIs and clinical phase products partially offset by lower sales of controlled substances.

Excluding the impact of the new revenue recognition standard, net revenue in the first nine months of 2018 decreased 5.4% compared to the first nine months of 2017 to $333,363.

Gross margins in the first nine months of 2018 decreased to 37.4% from 43.0% in the first nine months of 2017. Gross profit in the first nine months of 2018 was $146,800 compared to $151,592 in the same period last year. Excluding the impact of the new revenue recognition standard, gross margins in the first nine months of 2018 were 36.5%. Gross profit in the first nine months of 2018 would have been $121,698. The decrease was primarily driven by lower production volumes and higher raw material costs.

SG&A expenses of $35,236 in the first nine months of 2018 increased compared to $35,065 in the first nine months of 2017. The increase was mainly due to higher consulting costs associated with an operational excellence initiative (approximately $800) partially offset by an accounts receivable write-off in the third quarter of 2017 (approximately $700). Sales and marketing expenses were flat compared to the first nine months of 2017. SG&A, as a percentage of net revenue, was 9.0% and 10.0% in the first nine months of 2018 and 2017, respectively.

Research and development (“R&D”) expenses of $10,128 were 2.6% of net revenue in the first nine months of 2018, compared to $9,748 or 2.8% of net revenue in the first nine months of 2017. The increase was primarily driven by higher personnel costs (approximately $2,000) and the impact of foreign currency (approximately $200) partially offset by higher absorption of R&D expenses into inventory and cost of goods sold (approximately $2,000).

Operating profit in the first nine months of 2018 was $101,436 compared to $106,779 in the first nine months of 2017. Excluding the impact of the new revenue recognition standard, operating profit in the first nine months of 2018 would have been $76,334. The decrease in operating profit was due to lower gross profit and higher operating expenses as described above.

FDF

Net revenue was $5,154 for the period from acquisition date, September 12, 2018 through September 30, 2018. Excluding the impact of the new revenue recognition standard, net revenue was $6,296.

Gross margins were 32.1% and gross profit was $1,652. Excluding the impact of the new revenue recognition standard, gross margins were 28.0% and gross profit would have been $1,766.

SG&A expenses were $1,141 in the first nine months of 2018. SG&A, as a percentage of net revenue, was 22.1%.

FDF operating profit for the period September 12, 2018 through September 30, 2018 was $508. Excluding the impact of the new revenue recognition standard, operating profit would have been $622. Both exclude integration costs of $394.

The Company’s Corporate headquarters provides management and administrative services to support the Company, and consists of certain aspects of the Company’s executive management, corporate relations, legal, compliance, human resources, and information technology and finance departments. The Company allocates certain corporate expenses to each of its segments. SG&A expenses of $10,660 in the first nine months of

2018 decreased compared to $15,613 in the first nine months of 2017. The decrease was mainly due to lower personnel related costs (approximately $3,800) and lower due diligence costs, excluding Halo’s acquisition costs (approximately $700). R&D expenses of $1,812 in the first nine months of 2018 decreased compared to $2,842 in the same period last year. The decrease is due to the timing of spending on the development of generic drug products.

During the third quarter of 2018, the Company completed the acquisition of 100% of Halo, a finished dosage form Contract Development and Manufacturing Organization. All acquisition and integration costs have been expensed and totaled $7,727 for the nine months ended September 30, 2018, of which $394 was recorded by the FDF segment. These costs have been recorded to “Acquisition and integration expenses” on the Company’s income statement.

During the second quarter of 2018, the Company acquired a 19.9% equity investment in a European company (“Investee”). The Investee completed an initial public offering on a foreign exchange late in the quarter, which reduced the Company’s ownership share to 16.3%. The Company’s investment is subject to a one-year prohibition on selling the shares. The Company has one seat on the Board of Directors of the investee and concluded it is able to exercise significant influence and that equity accounting would be appropriate. In accordance with ASC 825, the Company has elected to record this investment at fair value. The Company selected an appropriate valuation methodology to compute a discount for the lack of marketability to be applied to the closing market price of the shares as of September 30, 2018. The fair value of the Company’s shares increased to $10,825 during the first nine months of 2018 resulting in an unrealized gain that was recorded as “Unrealized gain on investment in equity securities” on the Company’s income statement. Since the shares owned by the Company are substantially in excess of the daily trade volumes of the stock, it could be difficult to sell the shares in a timely manner when the restrictions lapse and it is possible the ultimate value to be realized by the Company could be significantly less upon a sale of the securities.

Net interest expense was $824 in the first nine months of 2018 compared to $991 in the first nine months of 2017. The decrease is due to higher interest income generated from higher cash balances partially offset by interest expense on borrowings during the quarter to fund the Halo acquisition. There was $325,000 outstanding on the Credit Facility at September 30, 2018. The average interest rate on debt was 3.6% in the first nine months of 2018. The Company did not have any debt outstanding as of September 30, 2017.

Income tax expense from continuing operations for the nine months ended September 30, 2018 and 2017 was a benefit of $872 compared to an expense of $22,484, and an effective tax rate of 26.1%, respectively. Excluding the impacts of immediately recognizing certain effects of share-based compensation, acquisition and integration expenses, unrealized gain on investment in equity securities, a $2,105 benefit for finalizing the TCJA toll charge, and a $12,189 benefit for release of a state valuation allowance and the revaluation of state deferred tax balances due to New Jersey tax reform enacted during the quarter ended September 30, 2018, the effective tax rate would have been 20.5% for the nine months ended September 30, 2018, compared to 32.1% for the nine months ended September 30, 2017.

Income from continuing operations in the first nine months of 2018 was $91,916, or $2.73 per diluted share, versus $63,515, or $1.90 per diluted share in the same period a year ago.

Excluding the impact of the new revenue recognition standard, income from continuing operations in the first nine months of 2018 was $72,004 or $2.14 per diluted share.

Liquidity and Capital Resources

During the first ~~nine~~three months of ~~2018~~2019, cash provided by operations was $3945,~~764~~558 versus $7224,~~085~~451 in the same period a year ago. This ~~decrease~~increase was primarily due to the timing of accounts receivable collections ~~and~~partially offset by increased inventory production. Contract assets represent unbilled revenue recognized.

3932

Cash flows used in investing activities in the first ~~nine~~three months of ~~2018~~2019 were $~~462~~267,~~508~~704 versus $3523,~~405~~791 in the same period a year ago. The ~~2018~~2019 cash flows include the acquisition of ~~Halo~~Avista for $~~418~~248,~~963~~145, ~~and~~a ~~capital~~residual ~~expenditures~~payment offor ~~$43,545.~~the ~~The~~Halo ~~2017~~acquisition ~~cash~~for ~~flows~~$322 ~~include~~and capital expenditures of $3819,~~241~~237. inThe ~~the~~2018 ~~same~~cash ~~period~~flows arepresent ~~year~~capital ~~ago~~expenditures. Capital expenditures in the first ~~nine~~three months of ~~2018~~2019 and ~~2017~~2018 primarily expanded the Company’s manufacturing capacity to support expected growth.

Cash flows provided by financing activities in the first ~~nine~~three months of ~~2018~~2019 were $~~337~~194,~~685~~453 compared to $32,~~448~~722 in the same period a year ago. The ~~2018~~2019 cash flows include borrowings of $~~325~~220,000 to ~~partially~~ fund the ~~Halo~~Avista acquisition ~~and~~partially ~~proceeds~~offset ~~from~~by ~~stock~~the ~~options~~pay ~~exercised~~down of debt of $1222,~~685~~500. The ~~2017~~2018 cash flows ~~include~~represent proceeds from stock options exercised ~~of $3,448~~.

The Company expects to spend approximately $7060,000 to $8070,000 on capital expenditures during ~~2018~~2019, excluding acquisitions.

~~The~~On January 2, 2019, the Company ~~has~~amended aand restated its Credit Facility by entering into an $~~500~~800,000 five-year Syndicated Senior Credit Facility~~. Borrowings~~ ~~under~~(“Credit ~~the~~Facility”), comprising of a $600,000 Revolving Credit Facility ~~bear~~and ~~interest~~$200,000 atTerm aLoan ~~rate~~A. ~~per~~The ~~annum~~Company is required to make minimum quarterly principal payments on the Term Loan A of ~~LIBOR~~$2,500 ~~plus~~through aDecember ~~margin~~2020, ~~ranging~~$3,750 ~~from~~through December 2022 and $5,000 through December 2023. The remainder of the principal is due on January 2, 2024. The Company pays interest on this Credit Facility at LIBOR plus 1.25% to- 2.00% based upon certain financial measurements. As ofThe ~~September~~Credit ~~30,~~Facility ~~2018,~~also ~~there~~includes financial covenants regarding interest coverage and leverage ratios. The Company was ~~$325~~in compliance with all financial covenants at March 31,~~000~~ ~~outstanding~~2019 onand ~~the~~December ~~Credit~~31, ~~Facility~~2018.

The Company believes that cash flows from operations, along with funds available from the revolving line of credit, will be adequate to meet the operational and debt servicing needs of the Company for the foreseeable future.

InThe ~~September~~Company’s ~~2018~~forecasted cash flow from future operations may be adversely affected by various factors including, but not limited to, declines in customer demand, increased competition, the ~~Company~~deterioration ~~completed~~in general economic and business conditions, increased environmental remediation, interest rates, returns on assets within the ~~acquisition~~Company’s ofdomestic ~~100~~pension plans, tax payments, as well as other factors. Our largest product (23.5%, or $120,989 of ~~Halo~~2018 ~~Pharma,~~sales) ais ~~finished~~used ~~dosage~~by ~~form~~our ~~Contract~~customer ~~Development~~to ~~and~~produce ~~Manufacturing~~an ~~Organization~~anti-viral drug. ~~The~~Our ~~deal~~sales ~~was~~of ~~structured~~this asproduct adeclined ~~stock~~significantly ~~purchase~~in ~~for~~2018 ~~consideration~~and we expect sales of approximately $~~425~~50,000~~. The~~ ~~Company~~- ~~utilized~~$55,000 ~~cash~~in on2019, ~~hand~~ and ~~borrowings~~approximately ~~under~~$15,000 ~~the~~- ~~credit~~$20,000 ~~facility~~in to2020, ~~pay~~the final year of the ~~purchase~~5-year ~~price~~supply agreement.

~~The~~As ~~Company’s~~discussed ~~forecasted~~more ~~cash~~fully ~~flow~~in ~~from~~Note ~~future~~16 ~~operations~~to ~~may~~the beConsolidated ~~adversely~~Financial ~~affected~~Statements, bythe ~~various~~Company ~~factors~~continually ~~including,~~receives ~~but~~additional ~~not~~information ~~limited~~to develop estimates to, ~~declines~~record inreserves ~~customer~~for ~~demand,~~remediation ~~increased~~activities ~~competition~~at Berry’s Creek and other environmental sites. These matters, either individually or in the ~~deterioration~~aggregate, could result in ~~general~~actual ~~economic~~costs that are significantly higher than the Company’s current assessment and ~~business~~could ~~conditions,~~have ~~increased~~a ~~environmental~~material ~~remediation,~~adverse ~~returns~~effect on ~~assets~~the ~~within~~Company's cash flows in future reporting periods. Based upon past experience, the Company’s ~~domestic~~believes ~~pension~~that ~~plans~~payments significantly in excess of current reserves, asif ~~well~~required, aswould ~~other~~be ~~factors~~made over an extended number of years.

~~Our~~See ~~largest~~the ~~product~~“Risk ~~(32.8%~~Factors” ofsection ~~2017 sales) is used by our customer to produce an anti-viral drug. Our customer's sales~~ of ~~this drug have been trending downwards and, accordingly, we expect our sales of this product to our customer to also trend downwards over~~ the ~~next~~Company’s ~~few~~Annual ~~years. We~~Report ~~have~~on aForm 510-~~year~~K ~~supply~~for ~~agreement~~the ~~ending~~period inended December ~~2020~~31, ~~that~~2018 ~~includes a defined minimum volume~~ for ~~2019, which represents a~~ further ~~significant~~explanation ~~decline~~of ~~compared~~factors tothat ~~the~~may ~~volumes~~negatively weimpact ~~expect to ship in 2018. There is no minimum volume stipulated in~~ the ~~agreement~~Company’s ~~for~~cash ~~2020~~flows.

As discussed more fully in Note 15 to the Consolidated Financial Statements, the Company continually receives additional information to develop estimates to record reserves for remediation activities at Berry’s Creek and other environmental sites. These matters, either individually or in the aggregate, could result in actual costs that are significantly higher than the Company’s current assessment and could have a material adverse effect on the Company's cash flows in future reporting periods. Based upon past experience, the Company believes that payments significantly in excess of current reserves, if required, would be made over an extended number of years.

See the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the period ended December 31, 2017 for further explanation of factors that may negatively impact the Company’s cash flows.

Impact of Recent Accounting Pronouncements

The following accounting pronouncements became effective for the Company January 1, ~~2018~~2019:

~~Revenue from Contracts with Customers~~Leases

In ~~May~~February ~~2014~~2016, the FASB issued ASU ~~2014~~2016-0902 which ~~introduces~~requires alessees ~~new~~to ~~five-step revenue recognition model in which an entity should~~ recognize ~~revenue~~right ~~to depict the transfer~~ of ~~promised~~use ~~goods~~assets orand ~~services~~lease toliabilities ~~customers~~on ~~in an amount that reflects~~ the ~~consideration~~balance tosheet ~~which~~for ~~the~~all ~~entity~~leases ~~expects~~with toterms begreater ~~entitled~~than intwelve ~~exchange for those goods or services~~months. Several

On January 1, 2018, the Company adopted the new accounting standard ASC Topic 606, Revenue from Contracts with Customers and all the related amendments (“new revenue standard”) to all contracts not completed as of January 1, 2018 using the modified retrospective method. The cumulative effect of initially applying the new revenue standard was $16,219 and has been recorded as an adjustment to increase the opening balance of retained earnings. The cumulative effect adjustment relates primarily to the recognition of revenue and costs for contracts that transfer promised goods or services over time. Gross sales, cost of goods sold, and tax expense of $51,896, $31,347, and $4,330 respectively, were recorded as part of the cumulative effect adjustment. The comparative information has not been restated and is reported in accordance with accounting standard Topic 605, which was in effect for those periods.33

~~Presentation~~updates were issued in 2018 and 2019 that provide clarification on a number of ~~Net~~specific ~~Periodic~~issues ~~Benefit~~and ~~Cost~~reporting ~~Related~~requirements. toThis ~~Defined~~standard ~~Benefit~~became ~~Plans~~effective for the Company on January 1, 2019. As a result of adopting this update, right of use assets of $37,984 and operating lease liabilities of a similar amount were recorded on the balance sheet for identified operating leases. See Note 11.

Scope of Modification Accounting, Stock Based Compensation

Business Combinations – Clarifying the Definition of a Business

Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments

Statement of Cash Flows – Restricted Cash

Recognition and Measurement of Financial Assets and Financial Liabilities

The following recently issued accounting pronouncements will become effective for the Company in future periods:

Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income

Effects of the Tax Cuts and Jobs Act

Improvements to Nonemployee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07 which aligns the accounting for share-based payment awards issued to nonemployees with those issued to employees. Under the new guidance, the nonemployee awards will be measured on the grant date and compensation costs will be recognized when achievement of the performance condition is probable. ~~This~~The ~~new~~update ~~standard~~became is effective ~~for~~on ~~fiscal~~January ~~years beginning after December 15~~1, ~~2018,~~2019 ~~including interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the new guidance~~ and ~~does~~did not ~~expect it to~~ have a material impact on ~~its~~the Company’s consolidated financial statements.

Targeted Improvements to Accounting for Hedging Activities

The following recently issued accounting pronouncements will become effective for the Company in future periods:

Changes to the Disclosure Requirements for Fair Value Measurement

Changes to the Disclosure Requirements for Defined Benefit Plans

Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract

~~Leases~~34

operating leases. The result of adoption will be an increase to assets and liabilities by the same amount for the identified operating leases. Several updates have been issued in 2018 that provide clarification on a number of specific issues and reporting requirements. The Company is currently evaluating the new guidance and does not expect the adjustment will be material to the Company, assuming there is not an increase in lease activity.

Simplifying the Test for Goodwill Impairment

Targeted Improvements to Accounting for Hedging Activities

In August 2017, the FASB issued ASU 2017-12 which improves the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. The standard also makes certain targeted improvements to simplify the application of the hedge accounting guidance. The amendment is effective for fiscal years beginning after December 15, 2018, including interim periods within that reporting period. The Company is currently assessing the impact that adopting this new accounting standard will have on its consolidated financial statements.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

There has been no significant change in the Company’s exposure to market risk during the first ~~nine~~three months of ~~2018~~2019. For a discussion of the Company’s exposure to market risk, refer to Part II, Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” contained in the Company’s Annual Report on Form 10-K for the period ended December 31, ~~2017~~2018.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934 (the “Exchange Act”), the Company carried out an evaluation, under the supervision and with the participation of management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the quarter covered by this report that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

4435

PART II - OTHER INFORMATION

CAMBREX CORPORATION AND SUBSIDIARIES

Item 1.

Legal Proceedings

See the discussion under Part I, Item 1, Note 1516 to the Company’s Consolidated Financial Statements.

Item 1A.

Risk Factors

There have been no material changes to the Company’s risk factors and uncertainties during the first ~~nine~~three months of ~~2018~~2019. For a discussion of the Risk Factors, refer to Part I, Item 1A, “Risk Factors,” contained in the Company’s Annual Report on Form 10-K for the period ended December 31, ~~2017~~2018.

Item 6.

Exhibits

Exhibit 10.1		Credit Agreement, dated January 2, 2019, by and among the Company, the Subsidiary Borrowers party thereto, the Subsidiary Guarantors party thereto, Wells Fargo Bank, National Association, as administrative agent, and the lenders party thereto from time to time (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K , filed January 8, 2019)
Exhibit 31.1*		Section 302 Certification Statement of the Chief Executive Officer.
Exhibit 31.2*		Section 302 Certification Statement of the Chief Financial Officer.
Exhibit 32.1**		Section 906 Certification Statements of the Chief Executive Officer and Chief Financial Officer.
Exhibit 101.INS*		XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
Exhibit 101.SCH*		XBRL Taxonomy Extension Schema Document
Exhibit 101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
Exhibit 101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
Exhibit 101.LAB*		XBRL Taxonomy Extension Label Linkbase Document
Exhibit 101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith

**	Furnished herewith

~~Attached~~Filed herewith as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets as of ~~September~~March 3031, ~~2018~~2019 and December 31, ~~2017~~2018, (ii) Consolidated Income Statements for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2018~~2019 and ~~2017~~2018, (iii) Consolidated Statements of Comprehensive Income for the three months ended March 31, 2019 and ~~nine~~2018, (iv) Consolidated Statements of Stockholders’ Equity for the three months ended ~~September~~March 3031, ~~2018~~2019 and ~~2017~~2018, (ivv) Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019 and ~~2017~~2018, and (vvi) Notes to Consolidated Financial Statements.

4536

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CAMBREX CORPORATION By /s/Gregory P. Sargen Gregory P. Sargen Chief Financial Officer, Executive Vice President ~~and~~Corporate ~~Chief~~Development ~~Financial~~& ~~Officer~~Strategy (On behalf of the Registrant and as the Registrant's Principal Financial Officer)

Dated: ~~November~~May 82, ~~2018~~2019

4637

Filing Compare · CAMBREX CORP